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 1 
ABSTRACT 
 
 
 Neuroprotective therapies have made little progress in the recent past. 
Vascular components of injury contributing to the development and progression of 
neuronal injury, the inability of drugs to pass the blood-brain barrier (BBB) and 
unsuitable animal models used for mimicking stroke pathophysiology have been 
recognized as major factors responsible of treatment failure. The molecular 
mechanisms underlying disturbances of BBB function after stroke are poorly 
understood. Microvascular cells are polarized cells forming a tight barrier, which is 
complemented by membrane-bound ATP-binding cassette (ABC) transporters both 
on the luminal and abluminal endothelial membrane, giving rise to two key features, 
BBB tightness and polarity. Both BBB tightness and polarity are dysregulated upon 
stroke. Our study was carried out to study the underlying molecular mechanisms 
regulating BBB integrity and polarity. As such, the relevance of liver X receptor 
(LXR), the role of the apolipoprotein ApoE and effects of hypercholesterolemia, a 
highly prevalent risk factor for vascular diseases were investigated. 
 
 By means of pharmacological studies using a LXR agonist, T0901317, using 
Western blots analysis, protein interaction studies and pull-down assays, we showed 
that LXR activation preserved BBB integrity and decreased BBB leakage after focal 
cerebral  ischemia induced by middle cerebral artery (MCA) occlusion, representing a 
promising strategy to prevent post-ischemic brain swelling, a frequent complication of 
ischemic stroke. On the molecular level, the anti-edematous effect was caused by 
deactivation of microvascular calpain-1/2 and MMP-2/9 protease activity, resulting in 
the stabilization of p120 catenin, thereby decreasing RhoA and increasing Cdc42 
activity, thus modulating the expression, phosphorylation and assembly of tight 
junction (TJ) proteins. BBB enhanced integrity did not influence BBB polarity, as 
upon LXR activation the expression of the ABC transporters ABCB1, ABCC1, ABCA1 
and ABCG1 expression was similarly increased.  
  
 By means of genetic knockout, protein delivery and pharmacological signal 
transduction inhibition experiments, we demonstrated that ApoE controls the 
polarized expression changes of ABC transporters following stroke, presumably via 
its receptor ApoER2, which is mainly expressed at the abluminal side of brain 
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capillaries and acts as sensor of BBB leakage. As such, ApoE binding to ApoER2 
deactivates Jun-Kinase-1/2 (JNK-1/2) and c-Jun, thus transcriptionally increasing 
luminal endothelial ABCB1 and decreasing abluminal ABCC1 expression, thereby 
reducing the accumulation of the pharmacological model compound FK506 in the 
ischemic brain. Interestingly, BBB tightness, as evaluated by measuring by serum 
IgG extravasation, was not influenced by ApoE deficiency. Based on our data, ApoE 
regulates an endogenous cellular response, which prevents the accumulation of 
potentially toxic blood-derived molecules in the ischemic brain, but also impedes 
brain pharmacotherapies. Deactivation of ApoER2, based on our data may represent 
a promising strategy to ameliorate drug delivery to the stroke brain. 
 
 Hypercholesterolemia is a major risk factor of ischemic stroke. By means of 
Western blots, protein-protein interaction and pull-down assays, we showed that 
hypercholesterolemia increases BBB leakage upon stroke without influencing ABC 
drug transporters. This increased permeability was accompanied by and exacerbated 
activation of calpain-1/2, MMP-2/9 and downregulation of TJ proteins under 
hypercholesterolemic conditions. The effect of hypercholesterolemia on BBB 
permeability was associated with the overexpression of the angiotensin II type 1 
receptor (AT1R), with overactivation of its downstream target RhoA and RhoA’s 
activator, the leukemia associated Rho GEF (LARG). Our results show that BBB 
tightness and polarity are regulated by separate mechanisms. Our results offer new 
perspectives for the treatment of cerebrovascular diseases. As such, LXR agonists 
might be used for the treatment of brain edema, ApoE regulation or ApoER2 
blockade might be a novel strategy to enhance neuroprotective drug entry. The 
effects of hypercholesterolemia on BBB integrity should be taken more thoroughly in 
account in translational stroke studies.  
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1 INTRODUCTION 
 
 
1.1 Blood-brain barrier (BBB) in central nervous system (CNS) diseases 
 The central nervous system (CNS) is a particularly vulnerable system. In 
contrast to other peripheral systems in the human body, the CNS is very sensitive to 
a wide range of chemicals, xenobiotics, plasma composition fluctuations and 
metabolites in the blood circulation, which can be very harmful and toxic for the CNS 
(Hawkins and Davis, 2005). The regulation of many important ions such as Na+, K+, 
and Ca2+, and other molecules like amino acids, oxygen and glucose, is crucial for 
neuronal survival and function (Hawkins and Davis, 2005). Therefore, tightly 
controlled brain homeostasis and narrowly regulated brain microenvironment are 
essential for a proper function of the brain.  
 This drastic control and regulation of the CNS homoeostasis and 
microenvironment unraveled the existence of a complex and dynamic interface 
between the CNS and the blood circulation. This interface that acts as an ion balance 
regulator, a nutriments transport facilitator and a physical barrier that protects the 
CNS from harmful and toxic molecules (Hawkins and Davis, 2005), is the blood-brain 
barrier (BBB).  
The presence of the BBB was first noticed by Ehlrich (Ehlrich, 1885), who 
observed that water soluble dyes almost stained all organs with two exceptions, the 
brain and the spinal cord. Ehlrich’s explanation was that the CNS has not, or has 
very low, affinity for this water soluble dye (Ehlrich, 1904). Later, experiments 
conducted by his student Goldmann showed that when a blue dye was administered 
directly in the cerebrospinal fluid (CSF), this dye stained all CNS and did not stain 
any peripheral system or organ (Goldmann, 1913). These experiments confirmed the 
presence of a specialized physical barrier separating the CNS from the blood 
circulation, limiting and restricting the dye exchange between the CNS and the blood 
circulation. This propriety of the BBB in strongly and narrowly controlling brain 
homeostasis, regulating brain microenvironment, and protecting the brain from 
exogenous molecules under physiological conditions is now considered to be the 
main challenge in CNS diseases. 
 4 
As mentioned above, in the CNS the BBB primarly plays a role in controlling 
brain homeostasis and regulating brain microenvironment. It constitutes a special 
tight physical barrier separating the blood circulation and CSF, contributes in proper 
function of the brain by allowing the entry of oxygen and nutriments, and protects the 
brain from harmful molecules by limiting their entry and accumulation into the brain 
(Hawkins and Brown, 2005). Due to the crucial role of the BBB in CNS function, the 
dysfunction of the BBB represents the centre of development and progression of 
many CNS diseases. As such, increased permeability is observed in ischemic stroke 
and brain trauma (IIzecka, 1996; Morganti-Kossmann et al., 2002) leading to brain 
edema and exacerbating neuronal injury. In multiple sclerosis (MS) the BBB 
dysfunction participates directly in the pathophysiology of MS (Minagar and 
Alexander, 2003), and contributes in the development of the disease. In brain 
cancers like glioblastomas, the BBB becomes very leaky with exaggerated 
angiogenesis leading to brain edema and enhancing tumor survival (Anderson et al., 
2008). Moreover, many other risk factors and peripheral diseases contribute in BBB 
loss of function, like obesity, hypercholesterolemia, diabetes and atherosclerosis (Iso 
et al., 2002; O'Regan et al., 2008; Hebert et al., 1995; Hebert et al., 1997; Dormandy 
et al., 2005; Methia et al., 2001; Hafezi-Moghadam et al., 2007). In addition to these 
pathophysiological events that compromise the function and the integrity of the BBB 
upon many CNS diseases, the BBB itself represents a major challenge in the context 
of brain pharmacotherapies. 
 
 In CNS diseases, the BBB prevents drugs from brain entry and accumulation 
(Pardridge, 2007a). The BBB does not act only as passive diffusion barrier, but rather 
it expresses different active and dynamic transporters that prevent and eliminate 
drugs from brain entry, and thereby profoundly influence brain drug levels (Dallas et 
al., 2006; Löscher and Potschka, 2005). The great advances achieved in medicine 
increased the human longevity, but in counterpart CNS diseases treatment did not 
follow this tendency due to multiple factors like neuronal regeneration limitations and 
challenges, and especially the lack of efficient drug delivery strategies to the 
diseased brain. Therefore, the need now for efficient clinical therapeutics that can 
offer a long-term treatment for CNS diseases is crucial. The role of the BBB in drug 
transport and elimination represents the major challenge in the development and the 
elaboration of efficient brain targeting drugs.  
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This fact contributed in the decline observed in CNS drug market because 
most drugs do not reach the diseased brain in sufficient quantities and are eliminated 
by the BBB (Pardridge, 2002). Only few lipophilic molecules that have very low 
molecular weight between 400-500 Da are able to cross the BBB (Pardridge, 2001), 
and only a small number of CNS diseases respond to such molecules under low 
doses like depression and pain. On the other hand other serious CNS diseases do 
not respond at all to these small molecules like stroke, Alzheimer and brain cancers 
(Ajay, Bemis and Murcko, 1999; Ghose et al., 1999). Therefore, understanding the 
pathophysiology of the BBB and the governing molecular events that compromise the 
function of the BBB, as well as the regulation of the drug transport systems existing 
on the BBB, constitute major axis that will allow in the future the development of 
efficacious strategies for successful CNS diseases treatment.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Blood supply to the brain: Scheme illustrating brain blood supply by main 
brain arteries. (Source: University of Rochester, Medical Center). 
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1.2 Biology of the BBB 
 
 The BBB is a selective barrier constituted by specialized endothelial cells 
forming the endothelial cell layers that dynamically interact with other cells in the 
brain especially pericytes, astrocytes and neurons. Compared to other peripheral 
vascular systems, the BBB adopts a special phenotype characterized by tight 
endothelial cell-cell contacts, providing high transendothelial electrical resistance 
(Zlokovic, 2008; Bazzoni and Dejana, 2004), which limit almost all large exogenous 
and endogenous molecules in the blood circulation from brain entry and 
accumulation, except some small and lipophilic molecules (Pardridge, 2001).  
 
The endothelial cell – cell contacts are constituted by specialized junctional 
complexes, the tight junctions (TJ) and adherens junctions (AJ) (Kniesel and 
Wolburg, 2000). TJ are formed by transmembrane proteins, such as occludin, 
claudins and junctional adhesion molecules (JAM), that to establish endothelial cell-
cell contacts tightly interact with accessory cytoplasmic proteins such as membrane 
associated guanylate kinase like proteins (MAGUK), e.g. zonula occludens proteins 
(ZO-1, ZO-2, ZO-3) (Del Maschio et al., 1999; González-Mariscal et al., 2000; 
Hawkins and Davis, 2005), and other proteins such as cingulin, afadin (AF6) and 7H6 
(Citi et al., 1988; Zhong et al., 1993). AJ are constituted by the membrane proteins 
cadherins. The main cadherins are cadherin-E, -P, and -N, which are single pass 
transmembrane glycoproteins that, for establishing cell-cell contacts, interact with the 
cytoplasmic proteins catenins, constituted by catenin-α, -β, -γ and p120 catenin  
(Takeichi, 1995; Schulze and Firth, 1993). 
 
In contrast to other catenins, p120 catenin function remains unclear. Unlike 
catenin-β, p120 catenin does not interact with catenin-α, implying more complex role 
in of p120 catenin in cell-cell contacts (Daniel and Reynolds, 1995). It has been 
suggested a role of p120 catenin in signal transduction (Daniel and Reynolds, 1999). 
It has been shown that p120 catenin expression is deregulated in many tumors, and 
linked to the degree of tumor aggressivity (Shimazui et al., 1996; Dillon et al., 1998; 
Jewhari et al., 1999). Moreover, a novel role of p120 catenin has been suggested in 
controlling cell membrane cytoskeleton and cellular motility (Daniel and Reynolds, 
1999).  
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Figure 2. Molecular composition of endothelial cell-cell contacts: Scheme 
illustrating brain endothelial cell contacts. In addition to JAM and endothelial selective 
adhesion molecule (ESAM), which are members of the immunoglobulin superfamily, 
the two most important proteins of TJ are occludin and claudins, which have four 
transmembrane domains and two extracellular loops. In the cytoplasm there are 
many important adaptor proteins such as zonula occludens (ZO-1, -2, -3) and Ca2+ 
dependent serine protein kinase (CASK), which bind to the intramembrane of 
transmembrane proteins. Other adaptor molecules are expressed such as cingulin 
and junction-associated coiled-coil protein (JACOP). Other signaling and regulatory 
proteins are expressed such as multi-PDZ-protein 1 (MUPP1), the partitioning 
defective proteins 3 and 6 (PAR3/6), membrane-associated guanylate kinase with 
inverted orientation of protein–protein interaction domains (MAGI-1, -2, -3), ZO-1-
associated nucleic acid-binding protein (ZONAB), AF6, and regulator of G-protein 
signaling 5 (RGS5), which control the interaction of the membranous components 
with endothelial cell cytoskeleton. AJ are very important in establishing endothelial 
cell contacts constituted mainly by cadherins such as vascular endothelial cadherin 
(VE-cadherin) and the platelet–endothelial cell adhesion molecule (PECAM) that 
mediates homophilic adhesion. The catenins, including p120 catenin, are very 
important for linking AJ to the cytoskeleton. (Source: Abbott et al. 2006). 
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In addition to the physical proprieties of the BBB, endothelial cells that form 
this barrier express variety of transmenbrane proteins that play an important role in 
BBB transport (Schinkel, 1999), such as ATP binding cassette (ABC) transporters; 
solute carriers (SLC) (Dahlin et al., 2009), e.g.  SLCO, SLC22A; lipid related 
receptors, e.g. LDLR and ApoER2; and endocytosis related receptors. All these 
transmembrane proteins regulate the dynamic exchange between the brain and the 
blood circulation, which assure a proper function of the brain by controlling many 
aspects of brain homeostasis (de Boer et al., 2003; Pardrige et al., 1985; Pardrige 
and Fierer, 1985; Zhang and Pardridge, 2001).  
 
1.2.1 Neurovascular unit 
 
 At the anatomical level the BBB is constituted by cerebral endothelial cells, 
astrocytes, pericytes, neurons, and the extracellular matrix, forming all together the 
neurovascular unit. Recently, the concept of neurovascular unit has emerged and 
has been adapted in investigating CNS physiology and pathophysiology, as it 
constitutes the functional unit of the BBB. Therefore, cell-cell interaction, crosstalk 
and signaling at the neurovascular unit have been shown to be crucial and essential 
for the function of the BBB. At the cellular level, brain endothelial cells forming the 
BBB differ from other endothelial cells by the high quantity of mitochondrial content 
(Oldendorf et al., 1977), the very low rate of endocytosis (Ballabh et al., 2004; 
Pardrige, 2002), the lack of membrane fenestrations (Fenstermacher et al., 1988), 
and the basal pinocytotic activity (Sedlakova et al., 1999).  
 
 Structurally, the neurovascular unit is formed by endothelial cells that interact 
with pericytes attached at the basal side of the endothelium. In addition to pericytes, 
endothelial cells are ensheathed by the basal lamina composed mainly of collagen 
type IV, heparin sulfate proteoglycans, laminin, fibronectin (Farkas and Luiten, 2001), 
constituting the extracellular matrix that provides a physical support for endothelial 
cells and pericytes. Brain percicytes are different from other pericytes in peripheral 
systems (Nehls and Drenckhahn, 1991) and cover up to 30% of brain microvessel 
circumference, and play an important role in regulating endothelial cell proliferation, 
survival and migration (Hellström et al., 2001). Moreover, percicytes have been 
shown to modulate the branching of brain microvessels (Hellström et al., 2001).  
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In addition to pericytes, the basal lamina is directly interacting with astrocyte 
end-feet that ensheathe more than 90% of brain microvessels, and this interaction 
plays a crucial and essential role in the function of the BBB (Davson and Oldendorf, 
1967). Astrocytes act also as scaffold cell by guiding neurons during development 
(Jacobs and Doering, 2010) and by directing newly formed brain microvessels 
(Zhang et al., 1999) 
 
Cell-cell interaction at the neurovascular unit plays a crucial role in regulating 
the function of the BBB. Therefore, the special phenotype of brain endothelial cells 
alone is not sufficient to explain the specificity of the BBB. It is well established that 
when isolated brain microvessel endothelial cells are cultured alone in normal culture 
medium, they form a leaky monolayer that does not reflect BBB phenotype in vivo. In 
contrast, when astrocytes and/or pericytes are added to the culture medium, the 
monolayer shows higher electric resistance, increased integrity and decreased 
permeability, thus reflecting to some level BBB phenotype in vivo (Neuhaus et al., 
1991). In parallel, polarized astrocytes induce endothelial cell polarization, and 
endothelial cell polarity is required to maintain astrocyte polarity, which translate a 
reciprocal role in maintaining the function of the neurovascular unit (Abbott et al., 
1992). Based on these observations, it is now well established that endothelial cell 
interaction sites with the endfeet of polarized astrocytes represent the major signaling 
sites at the neurovascular system. Interestingly, some studies have shown that even 
pericytes are able to induce BBB phenotype like astrocytes (Minakawa et al., 1991).  
 
1.2.2 Signal transduction at the neurovascular unit 
 
 As described above, the long term effect and crosstalk between astrocytic 
endfeet and endothelial cells are crucial for the proper function of the neurovascular 
unit and for inducing BBB phenotype. Beside the long term effect of astrocytes on 
endothelial cell, evidence pointed at similar important short term effect of astrocytes 
on endothelial cell mediated by different signaling molecules and ligands produced 
and secreted by astrocytes. As such, astrocytes secrete different signaling molecules 
like growth factors, cytokines, and neurotransmitters that act directly not only on 
neurons but also on endothelial cells and other components of the neurovascular 
unit. 
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Figure 3. Crosstalk and signaling at the neurovascular unit: Scheme illustrating 
signaling pathways at the neurovascular unit. The neurovascular unit is formed by 
capillary endothelial cells and pericytes that are surrounded by the extracellular 
matrix that forms the basal lamina, and astrocytic endfeet. Astrocytic endfeet link the 
neurovascular unit to neurons. It represents an important site of signaling of the BBB. 
a. In cell culture the capillary endothelial cells express different transporters and 
receptors, such as excitatory amino acid transporters 1–3 (EAAT1–3), glucose 
transporter 1 (GLUT1), L-system for large neutral amino acids (LAT1) and P-
glycoprotein (P-gp). b. Crosstalk between astrocytic endfeet and endothelial cells is 
necessary to induce and maintain the BBB. Different molecules secreted by 
astrocytes and endothelial cells play role in this signaling process through different 
receptors expressed at astrocytic endfeet and endothelial cells such as 5-
hydroxytryptamine (5-HT, serotonin), angiopoetin 1 (ANG1), basic fibroblast growth 
factor (bFGF), endothelin 1 (ET1), glial cell line-derived neurotrophic factor (GDNF), 
leukemia inhibitory factor (LIF), purinergic receptor (P2Y2), transforming growth 
factor-β (TGFβ), endothelium-specific receptor tyrosine kinase 2 (TIE2) ( Begley and 
Brightman, 2003; Schinkel, 1999; Mi et al., 2001). (Source: Abbott et al., 2006). 
 
 
a 
b 
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 The importance of the crosstalk between astrocytes and endothelial cells at 
the BBB has been demonstrated by many in vitro experiments. It has been shown 
that astrocyte-derived signaling molecules such as transforming growth factor-β 
(TGF- β), glial cell line-derived neurotrophic factor (GDNF), interleukin-6 (IL-6) and 
basic fibroblast growth factor (bFGF) modulate the morphology and the integrity of 
the BBB (Tran et al., 1999; Utsumi et al., 2000) 
 
As such, endothelial cells express many receptors (Mi et al., 2001), which 
upon activation by astrocyte-derived signaling molecules, regulate endothelial cell-
cell contacts by modulating TJ and AJ formation and assembly, affect the transport 
systems existing at the BBB, and regulate the activities of many enzymes at the BBB 
(Abbott and Romero, 1996). Interestingly, this mechanism is not unidirectional, as in 
parallel endothelium-derived leukemia inhibitory factor (LIF) that are secreted by 
endothelial cells has been shown to play an important role in inducing astrocytic 
differentiation (Mi et al., 2001). Besides astrocytes, recent evidence showed that 
pericytes also play a role in BBB integrity and genesis by mainly regulating matrix 
metalloproteinase-9 (MMP-9) (Elfont et al., 1989; Healy et al., 1993; Dehouck et al., 
1997).  
 
1.2.2.1 Regulation of BBB tightness 
 
Endothelial paracellular permeability at the BBB is mainly maintained by TJ 
and AJ, which are regulated by different complex mechanisms, among these 
mechanisms phopshorylation of TJ and AJ proteins (McCarthy et al., 1996; Hirase et 
al., 2001). TJ and AJ are phosphoproteins that can be phosphorylated on amino acid 
serine, threonine, and tyrosine residues. Although the exact phosphorylation sites of 
TJ and AJ proteins remain unknown, their phosphorylation state directly influences 
their assembly, dissociation and subcellular distribution, therefore controlling the 
integrity of the BBB (Sakakibara et al., 1997; Andreeva et al., 2001; Rao et al., 2002).  
 
It has been shown that the phosphorylation of TJ and AJ depends on the type 
of stimulus as well as the neurovascular microenvironment. A proper interaction 
between TJ components such as the interaction between occludin and ZO-1 is 
essential for maintaining the tightness of TJ complex, thus the tightness of the BBB. 
Occluding and ZO-1 interaction is dependent on the phosphorylation state of these 
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two proteins. For example, vascular endothelial growth factor (VEGF) induces serine 
/ threonine phosphorylation and redistribution of occludin and ZO-1 in mouse brain 
endothelial cells, and oxygen mediators induce primarily tyrosine phosphorylation 
and reorganization of the TJ complex (Harhaj  et al., 2006; Kago et al., 2006; Haorah 
et al., 2007). Moreover, AJ proteins such as VE-cadherin and β-catenin tend to be 
serine / threonine and tyrosine phosphorylated during brain endothelial barrier 
opening (Kirk et al., 2003; Potter et al., 2007).  
 
VE-cadherins represent the major protein of AJ, and play an important role in 
vascular integrity. VE-cadherins interaction with catenin-α, -β, -γ and p120 catenin is 
essential for AJ complex stability. The exact mode of interaction between AJ 
components remains not fully understood, but it seems that catenin-β and catenin-γ 
forms a complex with cadherins and catenin-α, whereas the latter forms a bridge 
coupling the complex to actin and therefore endothelial cells cytoskeleton (Bazzoni et 
al., 2000). The role of the last member of catenin family, p120 catenin, remains 
unclear but many reports have shown that this protein plays an important role in 
modulating signal transduction (Nagafuchi et al., 2001). 
 
As shown above, many molecular mechanisms control and modulate TJ and 
AJ expression, distribution and assembly. Recently, Rho GTPases have caught 
attention and have been shown to be major regulators of TJ formation, maintenance 
and disruption. Rho GTPases are members of the Ras superfamily small proteins, 
which act as molecular switches, regulating many essential molecular mechanisms, 
including actin dynamics, gene transcription, cell cycle progression and cell 
adhesion. The most studied Rho GTPases are RhoA, Rac1 and Cdc42; they exist in 
two conformational states: active guanosine triphosphate (GTP)-bound state and 
inactive guanosine diphosphate (GDP)-bound state. In the active GTP-bound state, 
Rho GTPases recognize, bind and activate specific target proteins called effectors, 
inducing specific signaling pathway and generating specific cell responses (Etienne-
Manneville and Hall, 2002).  
 
 
 
 
 
 13 
 
 
 
Figure 4. Rho GTPase activation and deactivation cycle: Rho GTPases switch 
between an inactive (GDP)-bound and active (GTP)-bound forms. The activation of 
Rho GTPases is initiated by guanine exchange factor (GEF) that stimulates GDP 
exchange by GTP. The active GTP-bound form binds and activates specific effector 
proteins initiating a signal transduction response. Translational modification with lipid 
moieties, e.g. farnesyl, geranyl-geranyl, is also an important factor in Rho GTPases 
activity, as it allows the attachment of the active GTP-bound form to the plasma 
membrane. Afterwards, GTPase activating protein (GAP) stimulates the hydrolysis of 
GTP into GDP and Pi, turning back Rho GTPases to the inactive GDP-bound form, 
terminating the signal transduction response. The GDP dissociation inhibitor (GDI) 
maintains the inactive GDP-bound form of Rho GTPases in the cytosol, therefore 
making them inaccessible for further activation by GEF. (Source: Etienne-Manneville 
and Hall, 2002). 
 
 
Upon activation by the active GTP-bound form of RhoA, RhoA effector the 
Rho-associated coiled-coil containing protein kinase (ROCK) promotes 
phosphorylation of the regulatory light-chain of myosin (MLC) on serine-19 and 
threonine-18 through phosphorylation of the myosin light-chain phosphatase (MLCP), 
therefore blocking MLC dephosphorylation. This site-specific phosphorylation of MLC 
in turn elevates myosin ATPase activity, leading to acto-myosin contraction (Nelson 
et al., 2004; Noma et al., 2006), causing long-lasting alterations in endothelial 
permeability.  
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On the other hand, Cdc42 activation controls the polarity of actin and 
microtubule cytoskeleton and promotes BBB integrity by enabling the assembly of TJ 
proteins, such as occludin and ZO-1 (Ramchandran et al., 2008; Cau and Hall, 2005; 
Fukuhara et al., 2003), and by the restoration AJ of endothelial barrier, and it was 
suggested that activating Cdc42 therapeutically may represent a possible strategy for 
endothelial barriers restoration (Broman et al., 2007; Kouklis et al., 2004).  Besides 
these molecular mechanisms and signaling pathways, calcium Ca2+ homeostasis and 
signaling are crucial in endothelial cells function and BBB integrity. For example, 
endothelial cells express different receptors such as chemokine receptors (CXCR4), 
monocyte chemotactic protein-1 (MCP-1) receptor (CCR2) that controls calcium 
homeostasis via the L-type calcium channel (LTCC), leading to endothelial cell 
function disruption (Foresti et al., 2009). Recently, MCP-1 has been shown to induce 
endothelial permeability by inducing proteases and enzyme activation and directly 
downregulating TJ proteins expression, localization and distribution (Stamatovic et 
al., 2003).  
 
1.2.2.2 Regulation of BBB polarity 
 
Structural, biochemical and functional studies have shown that brain 
endothelial cells have two functionally distinct compartments; luminal compartment 
(i.e. apical membrane) that faces and interacts with the blood circulation and 
abluminal compartment (i.e. basal membrane) that faces and interacts with brain 
parenchyma (Betz et al., 1980). The polarity of cerebral endothelial cells is crucial for 
BBB function in controlling brain homeostatic and microenvironment. Due to this 
polarity, some channels, receptors and transporters expressed at the BBB are 
exclusively localized at the luminal membrane of endothelial cells and others 
exclusively at the abluminal membrane of endothelial cells (Betz et al., 1980; Roberts 
et al., 1993; Roberts et al., 2008). As such, the polarized distribution of the apical Na+ 
channels and the basolateral Na+-K+-ATPase is crucial for endothelial cells isosmotic 
fluids transport (Betz et al., 2008). This sub-cellular distribution and polarity of these 
transporters and receptors are deeply influenced by BBB pathophysiological 
conditions. 
 
Although many studies have shown that TJ proteins contribute in the 
establishment and maintenance of this luminal - abluminal membrane polarity 
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(Förster, 2008), it is still controversial whether TJ are the main responsible of BBB 
polarity or just a consequence of an already established polarity (Förster, 2008). TJ 
alone cannot explain totally the polarity of the BBB, because some studies showed 
that TJ play an important role in abluminal protein polarity but does not play any role 
in luminal protein polarity (Roberts and Sandra, 1993). In parallel, astrocytes 
interacting with endothelial cells have been shown to play an important role in 
mediating BBB tightness and polarity (Janzer and Raff, 1987; El Hafny et al., 1996; 
El Hafny et al., 1997; Bauer and Bauer, 2000). 
 
 
1.3 Transport across the BBB 
 
As described above, the BBB constitutes a physical and selective barrier 
between the CNS and blood circulation. The presence of the special TJ between 
endothelial cells forming the BBB is responsible for the high electrical resistance that 
has been estimated to be in the range of 8000 Ω× cm2 in vivo (Smith and Rapoport, 
1986), which is far more higher than the electrical resistance of any other peripheral 
vascular system, where the average electrical resistance is in the range of 3-33 Ω× 
cm2 (Crone and Christensen 1981; Butt et al., 1990).  
 
This high electrical resistance restricts and limits the passage of a big number 
of molecules and compounds across the BBB. In parallel, the brain is characterized 
by its high metabolic demands, consuming up to 20% of total oxygen and almost 
25% of glucose (Rolfe and Brown, 1997). As such, a proper exchange between the 
brain and the blood circulation is crucial for the function of the brain. Although the 
BBB constitutes a tight physical barrier separating the brain and the blood circulation, 
the exchange is assured by special transport systems that are specific for the BBB. 
Therefore, to enter the brain, endogenous and/or exogenous compounds have to 
cross the BBB, either by passive diffusion for compounds and molecules that have 
low molecular weight (< 500 Da) and small lipophilic compounds, in addition to 
oxygen and CO2, or by receptor mediated endocytosis for larger compounds and 
molecules, e.g. insulin and leptin that are very important for a proper brain function 
(Pardridge, 2001; Pardridge, 2002).  
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In addition to these conventional ways of molecule passage, the BBB 
expresses specialized transporters and carriers like ABC transporters and solute 
carriers (SLC) that contribute in molecule transport and exchange across the BBB. 
On one hand ABC transporters act mainly as efflux transporters using energy to 
pump out of cells harmful molecules and limiting their brain entry. On the other hand, 
SLC carriers play an important role in the selective uptake of vital molecules that are 
necessary for the proper functioning of the brain. Importantly, ABC transporters 
represent a big challenge in CNS diseases pharmacotherapies by restricting 
protective drugs from brain entry and accumulation (Hermann and Bassetti, 2007). 
 
Figure 5. Different ways of transport across the BBB: The BBB restricts and 
controls the transport of molecules into the brain. The main routes of molecular 
transport across the BBB are a. the paracellular route, which is restricted by TJ for 
most hydrophilic molecules, b. the lipid membranes of the endothelium as a passive 
diffusion route for lipophilic molecules, c. endothelial cells express different 
transporters and carriers for glucose, amino acids, purine bases, nucleosides, 
choline and other substances, some of these transporters are energy-dependent, 
e.g. P-glycoprotein and act as efflux transporters, d. some proteins, like insulin and 
transferrin, are transported by specific receptor-mediated endocytosis and 
transcytosis, e. native plasma membrane proteins like albumin are poorly 
transported, but cationization can increase their uptake by adsorptive-mediated 
endocytosis and transcytosis. Drug delivery across the BBB is dependent on routes 
b-e. (Source: Abbott et al., 2006). 
a b c d e 
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1.3.1 ATP binding cassette (ABC) transporters  
 
ABC transporters have been discovered initially by oncologists, after observing 
a cross-resistance of cancers treated with different anti-cancer drugs to different 
cytotoxic agents to which they had never been exposed, resulting in chemotherapy 
resistance. Moreover, adding cells from these multi-drug resistant tumors into normal 
tissue culture resulted in chemotherapy resistance (Biedler and Riehm, 1970). For 
example, cancer cells obtained from Chinese hamsters have been shown to develop 
resistance to many drugs in vitro, like mithramycin, puromycin, vincristin, vinblastin, 
daunorubicin, mitomycine C and demecolcine after they had been pretreated with 
actinomycin D (Biedler and Riehm, 1970). Based on that, this selection of tumour 
cells by only one cytotoxic agent resulted in a cross resistance to various anti cancer 
drugs, which had been named multidrug resistance (MDR).  
 
Afterwards, many transmembrane protein transporters have been identified to 
play a role in multidrug resistance. Interestingly, they are expressed in cancer cells, 
and in different healthy tissues in multiple organs, like liver, kidney, gastrointestinal 
tract, brain.  ABC transporters represent a big part of these transmembrane protein 
transporters.  
 
1.3.1.1 Structure of ABC transporters  
 
In humans, so far 48 ABC transporters have been identified and described, 
and based on domains organization and gene homology, they have been classified 
into seven distinct subfamilies (ABC1, MDR/TAP, MRP, ALD, OABP, GCN20, White) 
(de Lange,2004; Leslie et al., 2005). ABC transporters seem to play an important role 
in the function of many organs and systems, as such it has been shown that 
mutations in many of these transporters are the main cause of many genetic 
disorders such as bleeding disorders (Albrecht et al., 2005), eye and liver diseases 
(Martinez-Mir et al., 1998; Jacquemin, 2000), where ABC transporters fail to extrude 
specific ligands across cell membranes.  
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In order to be functional, ABC transporters require a minimum of four domains. 
Two transmembrane domains (TMD) form the ligand binding sites that provide 
specificity, and two nucleotide binding domains (NBD) that bind and hydrolyze ATP to 
execute the translocation of the bound ligand. Importantly, the NBD, and not the 
TMD, are homologous throughout the family and have many characteristic motifs 
including the Walker A and B motifs that are common to many NBD, and others like 
the ABC signature, stacking aromatic D, H, and Q loops, which are unique to the 
family, and they have different glycosylation sites (GS) (Borst and Elferink, 2002; 
Gottesmann et al., 2002; Löscher and Potschka, 2005).  
 
In general, ABC transporters are structurally closely related and they differ 
mainly by the number of TMD and NBD and the GS. Therefore, ABC transporters can 
be classified into three major groups based on their structure models; similar to multi-
drug resistance transporter (Mdr-1; i.e. ABCB1), the multi-drug resistance-associated 
protein (Mrp-4, -5; i.e. ABCC4, 5) constitute the first group, which spins the plasma 
membrane with two membrane-spanning domains (MSD), and each is composed of 
six TMD, one NBD located within the intracellular segment and a second NBD at the 
MSD COOH-terminal end (Borst and Elferink, 2002; Gottesmann et al. 2002; Löscher 
et al.,2005). The second group, including Mrp-1, -2, -3 and -6 ( i.e. ABCC1, 2, 3, 6), 
is similar to the first structure model except they have a third MSD composed of five 
TMD at their NH2-terminal end that does not have a NBD. The third group is similar to 
the one of the half transporter breast cancer resistance protein (BCRP; termed 
sometimes MXR for mitoxantrone-resistance gene, officially termed ABCG2), 
consisting of only one MSD and one NBD located at the NH2-terminal end. It has 
been shown that ABCG2 play a role in drug efflux when it forms homodimers and/or 
heterodimers with another half transporters.  
 
 In general, all ABC transporters have a biochemical common feature as they 
are all glycosylated on their extracellular segments (Borst and Elferink, 2002; 
Gottesmann et al. 2002; Löscher and Potschka, 2005). 
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Figure 6. Structure models of ABC transporters: ABC transporters, generally, can 
be divided into three groups depending on their structure a. with two MSD and two 
NBD, b. with three MSD and two NBD, c. with one MSD and one NBD. 
 
 
 
a 
b 
c 
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1.3.1.2 Function of ABC transporters 
 
The substrate binding and transport by ABC transporters are still not totally 
understood, but it is accepted now that the ATP switch model is the mode of action 
that ABC transporters adopt (Higgins and Linton, 2004). In this model, binding of a 
substrate to its high affinity site on the TMD, induces a decrease in the activation of 
energy for the ATP dependent NBD dimerization. Moreover, binding of two ATP 
molecules at the dimer interface induces a conformational change in the TMD, 
resulting in the formation of a closed, sandwich like configuration, of NBD dimers that 
directly affect the substrate binding properties. These changes in the physical 
conformation of TMD and NBD decrease the affinity of the substrate to its binding 
site, inducing its release into the extracellular compartment. Afterwards, the bound 
ATP is hydrolyzed to ADP and Pi destabilizing and opening the closed NBD dimers, 
and the basal configuration of NBD and TMD is restored and ready for a new 
substrate binding and transport. Based on this ATP switch model, ABC transporters 
are active and energy dependent transporters where ATP binding and hydrolysis is 
crucial for proper transport mechanism, as ATP binding is necessary for drug 
transport and ATP hydrolysis is necessary for transporter restoration. 
 
 
 
 
 
 
Figure 7. ABC transporter function: Representative scheme of ABC transporter 
function. ABC transporters are energy-dependent. They carry molecules (drugs) 
using energy generated by ATP hydrolysis.  
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1.3.2 Physiological role of ABC transporters 
 
 All known ABC transporters have overlapping substrate affinity for many 
lipophilic and amphipathic natural products, such as bacterial, herbal and fungal 
toxins, as well as carcinogens, therefore considered cell detoxification systems 
(Leslie et al., 2005). In some organs, like brain, testis and placenta, ABC transporters 
protect these organs actively from toxic compounds, whereas in other organs, like 
intestine and kidney, they transport biologically active compounds produced in these 
organs into the circulation.  
 
The exact physiological role of Mdr-1 remains unclear, but it is known that it 
protects organs against toxic xenobiotics. Some studies, in parallel, found out that 
Mdr-1 functions also as flippase and is able to transport lipids, like phospholipids and 
simple glycoshingolipids from plasma membrane into the extracellular space 
(Orlowski et al., 2006; Sharom et al., 2005). Interestingly, other studies showed that 
Mdr-1 may contribute in the membrane associated hydrophobic amyloid-beta (Aβ) 
peptide clearance (Vogelgesang et al., 2004; Burk et al., 2005). Mdr-1 absence in 
mice did not reduce the viability of mdr-1a-/- mice, suggesting no essential role of 
Mdr-1 in cell survival.  
 
None the less, mdr-1a-/- mice brain showed increased sensitivity to the 
neurotoxic compounds ivermectin, and to the cytostatic drug vinblastinme compared 
to wildtype mice (Schinkel et al., 1994), and elevated levels of many drugs in different 
organs (Schinkel et al., 1995; Schinkel et al., 1996; Smit et al., 1999). Like Mdr-1, 
Mrp-1’s exact physiological role remains unclear, but based on observations that 
Mrp-1 has high affinity and transports leukotriene C4 (LTC4), it has been suggested 
that it could function as physiological transporter for LTC4, because in mrp-1-/- mice 
LTC4 release from eosinophils and mast cells in response to IgE mediated 
inflammation is reduced (Wijnholds et al., 1997). Mrp-1 has also been suggested to 
have a role in cell detoxification, as it has been shown that in mrp-1-/- mice the 
passage of Mrp-1 substrates from the blood to the cerebrospinal fluid increased 
(Wijnholds et al., 2000). 
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1.3.3 Brain distribution of ABC transporters 
 
ABC transporters are expressed in many different cell types where they 
contribute in the transport of various substances (Glavinas et al., 2002), and control 
many aspects of cell microenvironment (Ye and al., 2008). In CNS, many ABC 
transporters are expressed, mainly drug transporters, e.g. Mdr-1, Mrp-1, BCRP 
(Borst and Elferink, 2002; Löscher et al., 2005), preventing toxic compounds uptake, 
and facilitating toxic compounds elimination. In the brain, ABC transporters are 
mostly expressed on endothelial cells (Demeule et al., 2001; Soontornmalai et al., 
2006). The subcellular localization of ABC transporters is very important for their 
activity and function, for example, ABC transporters involved in multidrug resistance 
are predominately localized to the luminal membrane of cells (van Helvoort et al., 
1996; Abele and Tampé, 1999), but the accurate subcellular localization of different 
ABC transporters expressed on endothelial cells of the BBB remains unclear clear. 
Moreover, CNS pathophysiological conditions play an important role in ABC 
transporters expression, function and subcellular localization. As such in some CNS 
diseases, the expression of ABC transporters was found in addition to endothelial 
cells, in astrocytes, microglia and neurons (Pradridge et al., 1997; Zhang et al., 1999; 
Lee at al., 2001; Seegers et al., 2002). 
 
The existing data on ABC transporters expression and subcellular localization 
at the BBB showed that Mdr-1, Mrp-2, Mrp-4 and MXR (BCRP; ABCG2) are 
predominantly expressed and located at the luminal (i.e. apical) plasma membrane of 
endothelial cells forming the blood brain barrier, whereas Mrp-1, Mrp-3 and Mrp-5 are 
expressed and located at the abluminal (i.e. basolateral) plasma membrane of 
endothelial cells (Borst and Elferink, 2002). Other studies have shown luminal 
expression and localization of Mrp-1 and Mrp-5, and abluminal expression for Mrp-4 
(Löscher et al., 2005). Moreover, detailed studies using high resolution 
immunofluorescence staining (Soontornmalai et al., 2006) showed that Mdr-1 and 
Mrp-5 are both expressed and localized at the luminal plasma membrane of 
endothelial cells, and Mrp-1 at the abluminal plasma, whereas Mrp-2 and Mdr-3 were 
not detectable. 
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Figure 8. ABC transporter at the BBB: Many ABC transporters have been 
identified and shown to be expressed at the BBB. Their function is tightly dependent 
on the polarity of endothelial and their sub-cellular localization, a. some of them are 
expressed exclusively at the luminal side such as ABCB1, ABCC5 b. others 
exclusively at the abluminal side such as ABCC1 c. and some at both sides such as 
ABCC2. 
 
 
1.3.4 ABC transporter regulation at the BBB 
 
 The regulation of ABC transporters at the BBB is very complex. The molecular 
mechanisms that control the physiological expression of ABC transporters are largely 
unknown. Under pathophysiological conditions, many unspecific signaling pathways 
have been shown to contribute to some level in ABC transporters regulation, such as 
the extracellular-signal-regulated kinases-1/2 (ERK-1/2), protein kinase C (PKC), c-
Jun N-terminal kinase-1/2 (JNK-1/2), nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB), protein kinase B (PKB/Akt) and cyclooxygenase-2 (Cox-2) 
that upregulate ABCB1, and the tumor suppressor p53 that downregulates ABCC1 
expression (Wang and Beck, 1998).  
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 Interestingly, some studies showed that ABCB1 is specifically regulated by a 
member of the orphan nuclear receptors (ONR) superfamily, such as steroid and 
xenobiotic receptor (SXR) in humans and the pregnane X receptor (PXR) in rodents 
(Bauer et al., 2004; Löscher et al., 2005; Bauer et al., 2006). Moreover, it has been 
shown that PXR activation induces ABCB1 expression at the BBB, transporting 
amyloid-beta (Aβ) peptide and reducing the number of Aβ plaques in Alzheimer’s 
disease (Vogelgesang et al., 2004; Burk et al., 2005). 
 
 Recently, another member of the ONR superfamily, the liver X receptor (LXR) 
has caught attention. LXRs act as cholesterol modulators that upregulate the 
expression of ABC transporters involved in lipid transport such as ABCA1, ABCG1 
and ABCG8 (Morales et al., 2008). LXRs are members of the ONR family acting as 
transcription factors. They exist in two isoforms NR1H3 (LXRα) and NR1H2 (LXRβ), 
which are activated by their endogenous ligands, oxysterols (Schroepfer, 2000). 
Initially, LXR have been described as sterol sensors protecting cells from cholesterol 
overload by regulating genes involved in reverse cholesterol transport (Naik et al., 
2006).  
 
 The activation of LXR by synthetic agonists has been shown to provide 
protection against glucose intolerance, diabetes and atherosclerosis (Efanov et al., 
2004; Bradley et al., 2007), to provide anti-inflammatory effects under conditions of 
atherosclerosis and ischemic stroke (Bradley et al., 2007; Morales et al., 2008), and 
to regulate the expression of VEGF in macrophages (Walczak et al., 2004) 
 
 All these studies suggested a potent and profound effect of LXR activation on 
the vascular system by controlling molecular mechanisms in endothelial cells and 
regulating endothelial cell gene expression (Joseph et al., 2002). This observation 
was supported by recent results showing that LXRs are also involved in regulating 
the expression and activity of some drug metabolizing enzymes, therefore suggesting 
a broader function of LXR signaling beyond being sterol sensors (Wada et al., 2008). 
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1.4 BBB in ischemic stroke 
 
Ischemic stroke is caused mainly by the occlusion of a blood vessel, due to 
arterial embolism or thrombosis, in a specific region of the brain disturbing blood 
supply, initiating the ischemic cascade which leads to neuronal death and rapid loss 
of brain functions (Dirnagl et al. 1999). Ischemic stroke represents approximately 
85% of strokes. Stroke is the main cause of adult disability in the United States and 
Europe (Feigin, 2005), and It is now the second leading cause of death in the world 
after heart disease (Donnan et al., 2008).  
 
Recently, new report released by the American Stroke Association (ASA) 
indicated that stroke would become the first leading cause of death in the world by 
2030 (http://www.theheart.org/article/749039.do). In this report, statistics performed 
by World Health Organization (WHO) showed that out of 58 million worldwide deaths 
in 2005, 7.6 million were caused by heart diseases; 5.7 million were caused by 
cerebrovascular disease and 7.6 million caused by all cancers. Moreover, this report 
highlighted striking statistics that the number of deaths caused by all cancers will fall 
in the West, due to the progress in cancers treatments; on the other hand, deaths 
caused by stroke will continue to rise worldwide, mainly due to the lack of efficient 
treatments.  
 
As mentioned above, the occlusion of the brain blood vessel initiates the 
ischemic cascade, leading to the activation of many signaling pathways that 
compromise cell survival and function, such as glutamate mediated excitotoxicity, 
Ca2+ overload, oxidative stress and BBB dysfunction, inflammation and cell death 
(Mehta et al., 2007).  
 
The dysfunction of the BBB represents, by itself, an important factor in 
worsening ischemic stroke insult. As such, at the site of the infraction, ischemic 
stroke challenges BBB function mainly by the creation of an oxidative stress 
environment that generates free radicals and reactive oxygen species (ROS) 
production, which lead to endothelial cells apoptosis and necrosis (Toda et al., 2009), 
activation of set of molecular events that compromise endothelial cell function 
(Cosentino et al., 2001). 
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Figure 9. BBB pathophysiology in ischemic stroke: The response of endothelial 
cells forming the blood-brain barrier to ischemic stroke is dependent on injury 
severity. 
 
 
The stress signaling pathways initiated by ischemic stroke challenges the BBB 
integrity by disturbing the expression of TJ proteins such as occludin and ZO-1 
(Huber et al., 2001), in altering the phosphorylation of TJ proteins and negatively 
modulating TJ proteins assembly and interaction (Takenaga et al., 2009), thus 
decreasing endothelial cell-cell contacts, increasing endothelial cell detachment at 
the BBB, therefore increasing endothelial wall permeability.  At the acute phase of 
ischemic stroke, the high influx of Ca2+ into endothelial cells activates many signaling 
pathways and molecular events (Mehta et al., 2007) especially calpain proteases 
(Cao et al., 2007) and matrix metalloproteinases (MMP) (Zhao et al., 2004; Zhao et 
al., 2006; Gu et al., 2002), which are widely regarded as hallmarks of the breakdown 
of the BBB. 
 27 
Calpains are calcium-dependent non-lysosomal cysteine proteases that are 
ubiquitously expressed. Calpains consist of two isoforms, mu-calpain and m-calpain 
(calpain-1 and -2, respectively), both representing heterodimers of a common 28-kDa 
subunit with two different 80-kDa subunits (Goll et al., 2003). Calpain-1/2 activity is 
tightly controlled by calpastatin, its endogenous specific inhibitor. Calpastatin 
expression has been shown to decrease after stroke, increasing calpain-1/2 activity 
(Sedarous et al., 2003).  
 
MMP-2 (gelatinase A) and MMP-9 (gelatinase B) are zinc-dependent 
endopeptidases, promoting extracellular matrix degradation (Park et al., 2009). MMP-
2/9 are activated upon cerebral hypoxia and ischemia, increasing brain edema and 
exacerbating neuronal injury (Park et al., 2009; Zhao et al., 2004). MMP-9 activity is 
negatively regulated by calpain inhibitors (Tsubokawa et al., 2006), suggesting that 
calpain mediates matrix protease activation. While the molecular actions of calpains 
and MMPs are comparably well understood, not much is known about whether and 
how these proteases mediate BBB permeability. 
 
 
a       b 
 
 
 
 
Figure 10. Calpain and MMP-9 contribution in the pathophysiology of the BBB: 
Calpains are cysteine protease activity that requires Ca2+ a. ischemic stroke elevates 
Ca2+ activating calpians b. at the acute phase of ischemic injury, MMP-9 activation 
contributes in destabilizing the extracellular matrix contributing in the breakdown of 
the BBB. (Source: Okayama University, Department of Physiology; Zolkovic, 2006). 
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At the molecular level, many signaling pathways are activated at the acute 
phase of stroke contributing to BBB damage. As such, it has been suggested that 
Rho GTPases induce at least part of BBB permeability changes upon stroke 
(Schreibelt et al., 2007; Chrissobolis and Sobey, 2006).  
 
Rho GTPases are small G-proteins transducing signals by binding and 
activating downstream effectors (Etienne-Manneville and Hall, 2002). The most 
studied are RhoA, Rac1 and Cdc42. In endothelial cells, RhoA activation induces 
stress fiber formation, thus destabilizing TJ and increasing BBB leakage (Schreibelt 
et al., 2007; Hirase et al., 2001). Cdc42 activation controls cell polarity and promotes 
BBB integrity by enhancing cell-cell contact (Ramchandran et al., 2008; Cau and 
Hall, 2005; Fukuhara et al., 2003). 
 
All these factors contribute directly and indirectly in BBB damage, 
compromising BBB function, thus abolishing the protective role of the BBB in 
controlling the microenvironment at the site of infraction. This increased permeability 
and loss of function of the BBB causes the secondary progression of brain injury by 
increasing cerebral edema, promoting the recruitment and migration of macrophages 
and neutrophils into the infracted region, and increasing the inflammatory responses 
(Charo and Ransohoff, 2006). 
 
Besides these molecular events that affect BBB tightness, ischemic stroke 
induces the regulation of the ABC transporters expression at the BBB. As such, the 
ischemic cascade induces the activation of many signaling pathways that have been 
shown to contribute in the regulation of ABCB1 and ABCC1 expressions. We have 
previously shown that ABC transporters exhibit profound expression changes on the 
luminal and abluminal endothelial membrane of ischemic cerebral microvessels, 
which impede drug accumulation in the stroke brain. As such, the luminal transporter 
ABCB1 (previously: multidrug resistance transporter-1), which extrudes 
pharmacological compounds from the brain into blood, is upregulated (Spudich et al., 
2006), whereas the abluminal transporter ABCC1 (previously multidrug resistance-
associated protein-1), which carries drugs in the opposite direction from the blood to 
brain, is downregulated in response to stroke (Kilic et al., 2008).  
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Deactivation of ABCB1 by pharmacological inhibition or genetic deletion 
increased concentrations of neuroprotective compounds more strongly in ischemic 
than non-ischemic brain tissue by up to an order of magnitude (Spudich et al., 2006), 
whereas ABCC1 blockade decreased tissue levels by as much as hundred-fold (Kilic 
et al., 2008). The alterations in pharmacodistribution were associated with the gain or 
loss of survival-promoting drug activities (Spudich et al., 2006; Kilic et al., 2008), 
demonstrating that changes in ABC transporter expression influence drug efficacy in 
a clinically relevant way. The mechanisms responsible in the observed upregulation 
of ABCB1 (Spudich et al., 2006), and the downregulation of ABCC1 (Kilic et al., 
2008) at the blood-brain barrier of ischemic brains and their respective implication in 
neuroprotective drug entry and accumulation in the brain, are still not well 
understood.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Brain drug accumulation upon ischemic stroke: Upon stroke, ABCB1 
(i.e. Mdr-1) and ABCC1 (i.e. Mrp-1) balance seems to be highly important in 
controlling drug entry and accumulation into ischemic brain. Post-ischemic 
manipulation of this balance would contribute in enhancing blood-to-brain drug 
transport. 
Brain drug accumulation 
low 
Ischemic stroke 
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1.5 BBB in hypercholesterolemia 
 
 It is well established that high cholesterol level in blood is a major risk factor 
for stroke, as the vessels show exacerbated atherosclerosis (Suk et al., 2003). 
Recently, some studies have shown also a direct correlation between increased risk 
of stroke and obesity revealed by body mass index (BMI). Stroke therapies have 
made little progress in recent years. Several pharmacological compounds stabilizing 
BBB integrity or promoting neuronal survival in animal models of ischemic stroke 
were tested in stroke patients (O'Collins et al., 2006; Stroke Therapy Academic 
Industry Roundtable, 1999). Apart from thrombolytics, none of these compounds 
turned out to be effective in humans (O'Collins et al., 2006; Stroke Therapy Academic 
Industry Roundtable, 1999).  
 
 A major limitation of animal stroke studies is that mostly young animals without 
risk factors are evaluated (O'Collins et al., 2006, Hossmann, 2009). Such studies 
hardly mimic the pathophysiology of ischemic stroke in humans, which often affects 
elderly subjects with unfavourable life habits or cerebrovascular risk factors (O'Collins 
et al., 2006, Hossmann, 2009). Beside being risk factors for stroke, high levels of 
blood lipids contribute directly to ischemic injury, therefore worsening ischemic stroke 
outcome, by increasing lipids peroxidation catalyzed by reactive oxygen species 
(ROS) production, enhancing the oxidative stress and endothelial cells apoptosis 
(Takabe et al., 2010). Moreover, it has been shown that high cholesterol levels in 
blood promote cerebral microvessel extravasation of apo B lipoprotein-Aβ (Takechi et 
al., 2008), and that some lipid lowering agents like atorvastatin and pravastatin 
ameliorate the exaggerated BBB dysfunction caused by saturated fats and 
cholesterol (Cheng et al., 2009; Kalayci et al., 2005).  
 
The exposure of endothelial cells to low-density lipoprotein (LDL) and oxidized 
LDL (OxLDL) causes endothelial dysfunction by activating the lectin-like oxidized 
LDL receptor-1 (LOX-1), increasing endothelin and angiotensin II production and 
secretion (Chen et al., 2002; Galle et al., 2000), increasing the activation of MMPs 
leading to occludin degradation (Casas et al., 2010),  enhancing endothelial nitric-
oxide synthase (eNOS) removal and preventing the production of nitric oxide (NO) 
(Kincer et al., 2002). Moreover, hypercholesterolemia increases the level of oxLDL in 
serum, therefore worsening the ischemic injury (Uno et al., 2005). 
 31 
Although many ABC transporters are lipid transporters; the regulation of ABC 
transporters at the blood brain barrier by high cholesterol levels remains unclear. For 
example, some studies showed that when cholesterol levels became high, Mdr-1 
expression increases and plays a role in transporting the excess of cholesterol that 
can be toxic for endothelial cells from the phospholipid bilayer into the endoplasmic 
reticulum (ER) to be esterified by the acyltransferase enzyme (ACAT) to cholesteryl 
esters, that are less toxic, and therefore enhancing endothelial cells survival (Luker et 
al., 1999). 
 
 
1.6 BBB in brain tumors 
 
 Brain tumors are characterized by exagerated vascular leakage (Ewing et al., 
2006), causing edema mainly due to TJ disruption and to the excessive angiogenesis 
(Davies, 2002). Moreover, brain tumors are very resistant to chemotherapies 
(Szakacs et al., 2006). Interestingly, both the tumor cells and the vasculature express 
ABC transporters at high level (Kemper et al., 2004; Regina et al., 2001).   
 
The chemoresistance in cancers is complex due to the fact that this drug 
resistance can be intrinsic or acquired depending on the causes of ABC transporters 
expression, as cancer cells could constitutively express ABC transporters, and 
pharmacotherapies can induce ABC transporters expression. As mentioned above, 
most chemotherapeutics are lipophilic molecules that show a very high affinity for 
ABCB1 (Gottesmann et al., 2002). It has been shown using specific inhibitors for 
ABCB1 or ABCB1 ablation in mdr-1a/b-/- mice increase brain drug entry and 
accumulation increased in both healthy and tumors tissues (Kemper et al., 2003).  
 
These strategies were efficacious in increasing the anti cancer drug paclitaxel 
entry and accumulation, which led to a significant decrease in tumor volumes (Fellner 
et al., 2002). Therefore, ABCB1 expression and activity regulation strategy is 
regarded as promising in enhancing brain tumor chemotherapies. 
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1.7 BBB in epilepsy 
 
It has been shown that ~ 30% of epilepsy patients continue to get seizures 
and that despite optimized drug treatment (Löscher and Potschka, 2005).  
Interestingly, in epileptic patients exhibiting pharmacoresistance, elevated levels of 
Mdr-1 and Mrp-1 expression have been observed in brain capillaries as well as 
astroglial endfeet around epileptogenic focuses in medically intractable epilepsy 
(Tishler et al., 1995; Sisodiya et al., 2001; Sisodiya et al., 2002). These observations 
support the hypothesis of a possible role of ABC transporters in drug resistance. This 
hypothesis is reinforced by the fact that many widely used anti-epilptics, which are in 
majority lipophilic to enbale brain entry, are substrates of Mdr-1 (Löscher and 
Potschka, 2005). Unfortunately, brain levels of these anti-epileptics were not much 
increased after Mdr-1 inhibition in experimental studies and only less than twofold 
concentration increases are observed (Potschka et al., 2001; Rizzi et al., 2002).  
 
The major problem with respect to drug resistance experiments in epilepsy is 
the lack of appropriate control conditions from areas located outside the 
epileptogenic focus and from epileptic patients that are responsive to anti-epileptics. 
Controlled experimental studies in kainic acid-induced limbic seizures have revealed 
a transient increase in mdr-1 mRNA expression levels in the epileptic mouse 
hippocampus (Rizzi et al., 2002), indicating that epileptic seizures themselves may 
induce Mdr-1 expression. The upregulation of Mdr-1 in mice exhibiting limbic seizures 
has previously been shown to have decreased levels of   anti-epileptic drugs, such as 
phenytoin (Rizzi et al., 2002). In contrast the inhibition of Mdr-1 with verapamil has 
not only elevated anti-convulsant levels in rat brains with limbic seizures, but also 
enhanced the response of the seizures to oxcarbacepine (Clinckers et al., 2005). All 
these data indicate that Mdr-1 may be causatively involved in drug resistance.  In 
view of the moderate effects of Mdr-1 inhibitors of brain drug biodistribution, some 
skepticism remains whether Mdr-1 is indeed the major and predominant factor 
responsible of drug resistance in epilepsy. Understanding the molecular mechanisms 
involved in Mdr-1 and Mrp-1 expression in brain capillaries could be very valuable in 
this context.   
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1.8 BBB in multiple sclerosis 
 
Multiple sclerosis (MS) is a complex inflammatory disease associated with 
chronic inflammation of the CNS due to the autoimmune attacks directed against 
components of the myelin sheath, which leads to demyelination, axonal loss, and 
brain atrophy. MS lesions are characterized by the presence of mononuclear 
inflammatory infiltrates and reactive gliosis (Brosnan and Raine, 1996). It is now 
widely accepted that the BBB breakdown is the main key and the initial step in the 
development of inflammatory lesions (Minagar and Alexander, 2003).  Although the 
mechanisms involved in BBB breakdown and dysfunction remain unknown, it is 
supposed that this loss of function is associated with T cells and macrophages 
activation that secrete pro-inflammatory cytokines interleukin 1, 12 (IL-1, -12), tumor 
necrosis factor-α (TNF- α), and interferon- γ (IFN-γ), reactive oxygen and reactive 
nitrogen species (RNS) (Brosnan and Raine, 1996). These molecular events are 
involved in MS pathogenesis and contribute in the development of the disease. 
Moreover, the T cells activation alters TJ at the BBB increasing its permeability and 
allowing the infiltration of these cells into brain (Suidan et al., 2008). 
 
Mitoxantrone (MX) is a type II topoisomeras inhibitor that acts as an 
antineoplastic agent, and it used in many cancers treatment. MX is also used in MS 
treatment, mainly by decreasing the secondary progressive MS lesion and it 
contributes in extending the time between relapses in relapsing-remitting MS and 
progressive relapsing MS (Fox, 2006). The therapy of active MS with MX is limited 
because of its dose-dependent side effects.  
 
Moreover, MX is a substrate for the efflux carriers ABCB1 and ABCG2 that are 
expressed at the BBB (Spudich et al., 2006; Zhang et al., 2003), and it has been 
shown that there is a correlation between the single nucleotide polymorphisms 
(SNPs) in these two transporters and MX dose response, and therefore it was 
proposed that MX dosing could be assessed individually by using the (SNPs) of ABC 
transporters as a pharmacogenetic markers associated with clinical response to MX 
therapy in MS (Cotte et al., 2009).   
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1.9 BBB in Parkinson’s disease 
Parkinson's disease (PD) is a degenerative disorder of the CNS that impairs 
motor skills, behavior and speech (Rodriguez-Oroz et al., 2009). The BBB 
dysfunction in PD remains unclear.  A study, using PD rat model, found out that BBB 
was disrupted in the basal ganglia of these animals (Westin et al., 2006), whereas in 
other study using primates no disruption of the BBB was observed (Astradsson et al., 
2009).  Although BBB dysfunction is not causative in PD progression, a interesting 
study showed that at an advanced stage of PD, ABCB1 expression was decreased 
and was associated with severe BBB disruption (Bartels, et al 2008a), this study 
suggested a possible role of PD in reducing ABCB1 expression (Bartels, et al. 
2008b), increasing toxins accumulation in PD brain and contributing in PD 
progression. 
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2 AIM OF THE STUDY 
 
 
2.1 Part I: Effect of LXR activation on BBB tightness 
 
 Experimental stroke research has focused mainly on basic cellular 
mechanisms that cause irreversible neuron damage and on strategies that make 
neurons less vulnerable and more resistant to stroke. Such strategies were not 
successful. Recently, many reports have shown that cerebrovascular system 
represents an important target in stroke research and treatment. Therefore, 
understanding the molecular mechanisms involved in BBB dysfunction and 
preserving BBB function upon stroke represent new promising strategy for stroke 
treatment.  
  
 The molecular mechanisms involved in BBB dysfunction upon ischemic stroke 
are diverse. Ischemic stroke downregulates TJ proteins (Hubert et al., 2001), 
decreases BBB tightness, increases the activity of proteases (Cao et al., 2007; Zhao 
et al., 2004; Gu et al., 2002), increases endothelial membrane and basal lamina 
degradation (Lo et al., 2003), increases endothelial apoptosis (Lo et al., 2003) and 
deregulates endothelial active transports (Spudich et al., 2006; Kilic et al., 2008), 
leading to endothelial cell wall permeability and edema formation (Charo and 
Ransohoff, 2006). Although these molecular pathophysiological mechanisms are 
known to be activated upon stroke contributing in BBB damage, the upstream 
signaling pathways that control and regulate these pathophysiological mechanisms 
are not well characterized.  
 
 In this study we used C57Bl6/j submitted to 30 min focal cerebral ischemia to 
dissect the key molecular mechanisms involved in BBB dysfunction. In view of the 
profound effect of nuclear receptors on ABC transporter expression (see chapter 
1.3.4), we were interested in the effect of LXR activation on BBB tightness and 
polarity. As such, we examined how the LXR agonist T0901317 influences brain 
edema, BBB permeability and ABC transporter expression in ischemic brain 
microvessels. In these studies we wanted to understand whether BBB tightness and 
polarity share common mechanisms of regulation or whether both features of the 
BBB are differentially regulated. 
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2.2 Part II: Effect of apolipoprotein-E (ApoE) on BBB polarity 
 
A large number of neuronal survival promoting molecules known from different 
in vitro and in vivo studies were not successful in clinical trials (Danton and Dietrich, 
2004; Hoyte et al., 2004). Drug access to the diseased brain tissue is a major 
hampering factor for CNS – targeting therapies. The upregulation of ABC 
transporters at the luminal endothelial membrane is thought to contribute to 
neuroprotection failure by preventing drugs from reaching therapeutic tissue level. 
Indeed, we have previously shown that ABCB1 inhibition strategies (Spudich et al., 
2006) improve neuroprotective drug accumulation in the ischemic brain upon stroke 
enhancing stroke outcome. In addition, we have previously shown that ABCC1 acts 
as gateway for drug accumulation in the brain (Kilic et al., 2008) is downregulated at 
the abluminal endothelial membrane upon stroke. These results showed the 
importance of BBB polarity in drug transport, as ischemic stroke specifically 
upregulates ABCB1 at the luminal side and downregulates ABCC1 at the abluminal 
side impeding drug accumulation in the brain.  
 
 The molecular mechanisms underlying the polarity changes of ABC 
transporters at the BBB upon ischemic stroke are unknown. Understanding these 
mechanisms might offer insights into the functioning of the BBB, and it may allow 
identifying targets via which drug access to the ischemic brain may be improved. In 
the preparation studies for this thesis using apolipoprotein-E knockout (ApoE)-/- mice, 
which originally were studied in order to characterize expression changes of ABC 
transporters in the atherosclerotic brain, we observed that adolescent ApoE-/- mice 
that were held on regular diet and therefore did not exhibit atherosclerosis, revealed 
a fundamentally altered expression pattern of ABCB1 and ABCC1 upon stroke, 
ABCB1 being downregulated whereas ABCC1 being upregulated in response to 
stroke.  
 
 We therefore characterized in a more systematic way ApoE’s role in the 
regulation of ABC transporters, demonstrating that ApoE itself controls the polarity of 
ABC transporter expression. 
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2.3 Part III: Effect of hypercholesterolemia on the ischemic BBB  
 
 Hypercholesterolemia induced by excess or high-calory food is a highly 
prevalent condition in ischemic stroke patients. In large clinical trials or patient 
registries, ~45-60% of patients exhibit elevated serum cholesterol levels (Sacco et 
al., 2008; Röther et al., 2008). Cholesterol levels above 7,0 mmol/l are associated 
with an elevated stroke risk (Leppälä et al., 1999), which in clinics may successfully 
be reduced, by cholesterol-lowering drugs (Amarenco et al., 2006). In view of the 
huge importance of hypercholesterolemia for stroke pathology; it is surprising that not 
much is known from experimental studies about how dietary influences affect acute 
stroke development.  Moreover, in caucasians, prior use of statins has recently been 
shown to be associated with enhanced stroke outcome (Leppälä et al., 1999). In that 
study, the beneficial effects were explained by pleiotropic effects of statins, as such 
leaving the question open as whether elevated cholesterol levels influence 
cerebrovascular injury.  
 
 Moreover, in mice exhibiting enhanced atherosclerosis induced by 
apolipoprotein-E (ApoE)-/-, enhanced BBB permeability has previously been reported 
upon cortex trauma and ageing when animals were placed on a cholesterol-rich diet 
(Methia et al., 2001; Hafezi-Moghadam et al., 2007). In these studies the authors did 
not observe BBB breakdown in wildtype animals undergoing cortex trauma (Methia et 
al., 2001), suggesting that the ApoE-/- was responsible for the dietary effects. The 
question whether and how hypercholesterolemia influences BBB integrity after stroke 
was so far unknown.  
 
 In view of the lack of evidence, we examined the effect of a cholesterol-rich 
(so-called Western) diet on brain edema, BBB tightness and polarity and investigated 
the molecular mechanisms involved, using C57Bl6/j  and ApoE-/- mice submitted to 
30 min MCA occlusion. With these experiments, we wanted to understand, whether 
unfavorable dietary habits, which are highly prevalent in stroke patients, affect BBB 
functioning after stroke. 
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3 MATERIALS AND METHODS 
 
 
3.1 Animal groups and pharmacological experiments 
 
Animal experiments were done according to the NIH guidelines for the care 
and use of laboratory animals.  
 
 For part I: Six weeks old C57BL6/j mice (20-25 g) were divided into two groups 
that were intraperitoneally treated one week prior to stroke with (a) 5% ethanol in 0.1 
M phosphate-buffered saline (PBS; vehicle) and (b) the LXR agonist T0901317 (1.25 
mg/ animal; 270-309-M050; Alexis Biochemicals, San Diego, CA, USA) dissolved in 
5% ethanol in 0.1 M PBS (n = 8 animals each). 
 
 For part II: In a first set of studies, Six weeks old C57BL6/j wildtype and ApoE-
/- mice (20-25 g) were subjected to 30 min MCA occlusion followed by 24 hours 
reperfusion. These animals were used for a detailed analysis of cell signaling 
changes of ischemic cerebral microvessels by Western blotting, immunoprecipitation 
and immunohistochemical analysis (n = 8 animals each) and qRT-PCR (n = 4 
animals each). To evaluate the relevance of the signal changes for ABC transporter 
expression, a second set of ApoE-/- mice were submitted to 30 min MCA occlusion. 
These animals were treated with (a) 500 µl of normal saline containing 20% 
dimethylsulfoxide (DMSO) (vehicle), (b) recombinant human ApoEε3 (50 µg; 
Invitrogen, Karlsruhe, Germany) diluted in 500 µl normal saline/ 20% DMSO, or (c) 
the JNK-1/2 pathway inhibitor SP600125 (1.25 mg) (Calbiochem, Bad Soden, 
Germany) diluted in 500 µl normal saline/ 20% DMSO (n = 4 animals each), which 
were intraperitoneally administered twenty-two hours after reperfusion, i.e., two hours 
before animal sacrifice.  And to study the functionality of the ABCB1 transporter, a 
third set of C57Bl6/j and ApoE-/- mice underwent 30 min of MCA occlusion. Nineteen 
hours after reperfusion, animals were treated intraperitoneally with the ABCB1 
substrate FK506 (3 mg kg-1, diluted in 150 µl 0.9% NaCl / 10% ethanol / 1.6% Tween 
80; obtained from Fujisawa, Munich, Germany). Three hours later, one set of ApoE-/- 
animals (n = 5 animals) received intraperitoneal injections of recombinant human 
ApoEε3 (50 µg, diluted in 150 µl 0.9% NaCl; Invitrogen, Karlsruhe, Germany), all 
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other animals being treated with vehicle (150 µl 0.9% NaCl) (n = 5 animals / group). 
Animals were sacrificed three hours after this injection. 
 
 For part III: Six weeks old C57BL6/j (20-25 g) were divided into two groups: a) 
mice fed with normal diet chow (Normal Diet), b) mice fed western diet (TD.88137) 
chow (Western Diet) for 6 weeks as hypercholesterolemia model. Mice were 
subjected to 30 min MCA occlusion followed by 24 hours reperfusion (n = 8 animals 
each). These animals were used for a detailed analysis of cell signaling changes of 
ischemic cerebral microvessels. 
 
 
3.2 Induction of focal cerebral ischemia 
 
For the induction of focal cerebral ischemia, animals were anesthetized with 
1% isoflurane (30% O2, remainder N2O). Rectal temperature was maintained 
between 36.5 and 37.0°C using a feedback-controlled  heating system. Laser Doppler 
flow (LDF) was monitored using a flexible 0.5 mm fiberoptic probe (Perimed, 
Stockholm, Sweden) attached to the intact skull overlying the MCA territory (2 mm 
posterior / 6 mm lateral from bregma). LDF changes were measured during 30 min of 
MCA occlusion and up to 15 min after reperfusion onset. Focal cerebral ischemia 
was induced using an intraluminal filament technique (Figure 12).  
 
 Briefly, a midline neck incision was made, and the left common and external 
carotid arteries were isolated and ligated. A microvascular clip (FE691, Aesculap, 
Tuttlingen, Germany) was temporarily placed on the internal carotid artery. A 8-0 
nylon monofilament (Ethilon; Ethicon, Norderstedt, Germany) coated with silicon 
resin (Xantopren, Bayer Dental, Osaka, Japan; diameter of the coated suture: 180-
200 µm) was introduced through a small incision into the common carotid artery and 
advanced 9 mm distal to the carotid bifurcation for MCA occlusion. Thirty minutes 
after MCA occlusion, reperfusion was initiated by withdrawal of the monofilament. 
After the surgery, wounds were carefully sutured, anesthesia discontinued and 
animals allowed to recover.  
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Figure 12. Middle cerebral artery (MCA) occlusion model: Representative 
scheme where the nylon microfilament is introduced via the common carotid artery 
(CCA) up to the middle cerebral artery (MCA), obstructing blood circulation. 
 
 
Twenty-four hours after reperfusion, animals were reanaesthetized, and 
sacrified by transcardiac perfusion with 20 ml heparinised normal saline solution 
followed by 20 ml of normal saline. For drug biodistribution studies animals were first 
anaesthetized and blood was collected from heart in EDTA-coated tube and kept in -
20°C. Animal were then sacrified by transcardiac perfusion with 10 ml heparinised 
normal saline solution followed by 10 ml of normal salinemice.  
 
Brains were removed and cut on a cryostat into 20 µm thick coronal sections 
that were retrieved at the rostrocaudal level of the bregma, which represents the level 
of the midstriatum, at which MCA infarcts are most reproducible. In addition, tissue 
samples were collected from the ischemic and contralateral non-ischemic MCA 
territory (striatum and overlying parietal cortex) for Western blotting, 
immunoprecipitation, pull down, co-precipitation experiments and proteases activity 
assays.  
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3.3 Infarct and edema size evaluation studies 
 
To evaluate infarct and edema size, representative brain sections were 
stained with 0.5% cresyl violet. On these sections, the border between injured and 
non-injured, healthy tissue was outlined with image analysis software (Image j; NIH, 
Bethesda, MD) and the lesion area was calculated by subtracting the area of non-
lesioned tissue on both sides of the brain, and brain swelling area by subtracting the 
area of ipsilateral hemisphere from the contralateral hemisphere. 
 
 
3.4 IgG extravasation studies 
 
 Upon ischemic stroke, BBB damage and opening lead to the extravasation of 
serum constituents as serum proteins and serum IgG into brain. IgG entry and 
extravasation is correlated with the severity of BBB damage. Serum IgG 
immunohistochemisrty and quantification assess the degree of blood-brain barrier 
damage.  
 
 For this purpose, the 20 µm thick cryostat brain sections obtained from the 
midstriatum level were used. Sections were rinsed slightly and gently for 5 min at 
room temperature in 0.1 M PBS to not remove endogenous intravascular IgG, and 
fixed for 15 min at 4 °C with 4% paraformaldehyde /  0.1 M PBS (Kilic et al., 2006). 
Due to the presence of endogenous peroxidase, brain sections were first treated with 
methanol/ 0.3% H2O2 to block the endogenous peroxidase. Afterwards, treated brain 
sections were immersed in 0.1 M PBS containing 5% bovine serum albumin and 
normal goat serum (1:1000), sections were incubated for 1 h in biotinylated goat anti-
mouse IgG (sc-2039; Santa Cruz Biotechnology, Nunningen, Switzerland) and 
stained with an avidin peroxidase kit (Vectastain Elite; Vector Labs., Burlingname, 
CA) and diaminobenzidine (DAB; Sigma, Deisenhofen, Germany).  
 
Finally brain sections were immersed in alcohol bath and finally in xylen, and 
after coverslipping, sections were scanned and evaluated by analyzing the IgG 
extravasation in brain. 
 
 
 42 
3.5 Microvessel isolation and protein extraction 
 
Brain homogenates are not appropriate for studying protein expression and 
interaction at the BBB, because many proteins are exclusively expressed in brain 
microvessels. In total brain homogenates these proteins will be present in very low 
concentration. Moreover, some proteins are expressed in the whole brain, in the BBB 
and other cells, thus making it difficult to interpret any changes in protein expression. 
Therefore we firstly isolated brain microvessels using dextran separation technique, 
which is the most robust technique in microvessels isolation allowing the isolation of 
99% pure microvessels.  
 
 Tissue samples from animals belonging to the same group were pooled and 
mildly homogenized in a glass Teflon® homogenizer in ice-cold microvessel isolation 
buffer (MIB; 15 mM HEPES, 147 mM NaCl, 4 mM KCl, 3 mM CaCl2 and 12 mM 
MgCl2), supplemented with 5% protease inhibitor cocktail (P8340; Sigma, 
Deisenhofen, Germany) and 1% phosphatase inhibitor cocktail 2 (P5726; Sigma). 
Homogenates were centrifuged at 3,200 rpm for 10 min at 4°C. The resulting pellets 
were resuspended in 20% dextran (MW 64,000-76,000; D4751, Sigma) in MIB. 
Suspensions were centrifuged at 6,500 rpm for 20 min at 4°C. The resulting crude 
microvessel rich pellets were resuspended in MIB and filtered through two nylon 
filters of 100 µm and 30 µm mesh size (Millipore, Schwalbach, Germany).  
 
 The quality of trapped microvessels in 30 µm filters was checked. 
Microvessels were stored at -80°C until further use. Isolated microvessels were 
homogenized and lysated in NP-40 lysis buffer supplemented with 5% protease 
inhibitor cocktail and 1% phosphatase inhibitor cocktail 2. Lysate samples were 
sonificated over 2 cycles lasting 20 seconds each at 4°C at 40% power. Protein 
concentrations were measured using Bradford assay kit with an iMark Microplate 
Reader (Bio-Rad, Hercules, Ca, USA).  
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3.6 Western blot analysis 
 
To evaluate total and phosphorylated protein expression levels, the semi-
quantitative Western blot was used. For all experiments, 5X SDS loading buffer was 
added to lysate samples or blood serum samples containing equal protein quantities 
(20 µg). These samples were heated for all protein analysis studies except ABCB1 
and ABCC1, for which samples were loaded without heating to avoid aggregation of 
the highly glyosylated trans-membrane proteins. The loaded samples were subjected 
to sodium dodecylsulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) followed 
by Western blot analysis, using primary antibodies diluted 1:100 for ABCC1 and 
1:1,000 for all other proteins in 5% skim milk (Sigma) and 0.1 M tris buffered saline-
Triton-X100 (TBS-T).  
 
 For total and phosphorylated protein analysis by Western blot analysis the 
following antibody were used: Anti-ApoE (sc-6385, detecting murine ApoE), anti-
human ApoE (sc-6383, detecting human ApoE), anti-ABCB1 (sc-8313), anti-LXRαβ 
(sc-1000), anti-calpain-1/2 (sc-58326), anti-calpastatin (sc-20779), anti-ABCG1 (sc-
11130), anti-occludin (sc-27151), anti-RhoA monoclonal (sc-418), anti-RhoA 
polyclonal (sc-179), anti-Cdc42 (sc-6083) and anti-CD31 (sc-8306), anti-LARG (sc-
25638) anti-goat-anti-rabbit-HRP (sc-2004), anti-goat-anti-mouse-HRP (sc-2005) and 
anti-donkey-anti-goat (sc-2020) were purchased from Santa Cruz Biotechnology 
(Nunningen, Switzerland). Anti-p120 catenin (4989), anti-cleaved caspase-3 
(Asp175) (9661), anti-total-JNK1/2 (9252), anti-phosphorylated JNK1/2Thr183/Tyr185 
(9255), anti-total MMP-2 (4022), anti-total MMP-9 (3852) and anti-β-actin (4967) 
were purchased from Cell Signaling (Allschwil, Switzerland). Anti-ApoER2 (ab52905) 
was obtained from Abcam (Cambridge, U.K.), anti-JIP1/2 (34-5300) and anti-GFAP 
(18-0063) from Invitrogen anti-ABCA1 (NB400-105) from Novus Biologicals 
(Cambridge, UK), anti-ZO-1 (40-2300) from Invitrogen (Karlsruhe, Germany), and 
anti-ABCC1 (ALX-801-007-c250) from Alexis Biochemicals (San Diego, CA, USA). 
Primary antibodies were detected with horseradish peroxidase (HRP)-conjugated 
secondary IgG that were diluted 1:5000 in 5% skim milk and TBS-T and revealed by 
enhanced chemiluminescence plus (ECL) solution (Amersham International, 
Buckinghamshire, England). Films were digitized and quantified using ImageJ (NIH, 
U.S.A.) image processing software. 
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3.7 Rho GTPase affinity binding (=pull down) assays 
 
 Rho GTPases pull down assay is an in vitro technique used to study Rho 
GTPases activation (i.e. GTP-bound) in cell lysate samples. The active GTP-bound 
form of Rho GTPases binds specific effectors that are tagged by glutathione S-
transferase tail (GST-Effectors) and immobilized on glutathione agarose or 
sepharose beads (GST-Effectors). The Bead-GST-Effectors bind only the active 
GTP-bound form of Rho GTPases, which can be quantified afterwards. 
 
 
Figure 13. Affinity binding assay: GST-Effectors immobilized on beads are loaded 
in cell lysate samples. GST-Effectors effectors bind only the active GTP-bound form 
of Rho GTPase, which can be quantified and analyzed by Western blot. 
 
 
To make quantitative analysis, equal protein quantities (800 µg) of lysates 
obtained using a MgCl2 lysis buffer containing 50 mM Tris base, 100 mM NaCl, 2 mM 
MgCl2 and 1% NP-40 (pH 7.4) were added in Eppendorf tubes and complemented to 
a total volume of 1 ml by adding MgCl2 lysis buffer. To study and quantify Cdc42 
activation, Cdc42 affinity binding assay was applied. A volume of 20 µl (20 µg) of 
recombinant Wiskott-Aldrich syndrome protein (WASP) - Cdc42 binding domain of 
WASP (CDB) - glutathione S-transferase (GST), GST-WASP-CDB, (WS03; 
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Cytoskeleton Inc, Frankfurt, Germany) prefixed on agarose beads were loaded into 
prepared lysates and incubated under slight rotation overnight at 4°C. The next day, 
samples were centrifuged for 30 seconds at 15,000 rpm, supernatants removed and 
pellets washed three times in ice cold MgCl2 lysis buffer. A volume of 20 µl of 2X 
SDS plus 5% 2-mercaptoethanol loading buffer was added to each sample and 
boiled for 5 minutes (Heater Plate, Eppendorf, Germany), followed by a short 
centrifugation at 4,000 rpm to precipitate beads. Supernatants from each sample 
were subjected to SDS-PAGE using 12.5% acrylamide-bis gel. To study and quantify  
RhoA activation, RhoA affinity binding assay was applied, where a volume of 50 µl 
(20 µg) of recombinant Rhotekin (RTK) - Rho binding domain (RBD) - glutathione S-
transferase (GST), GST-RTK-RBD, (RT02; Cytoskeleton Inc) prefixed on beads were 
loaded according to the same protocol of Cdc42 binding assay. For total Cdc42 and 
RhoA detection, lysate samples were loaded in 12.5% SDS-PAGE, followed by 
Western blot analysis using anti-Cdc42 (sc-6083; Santa Cruz Biotechnology) or anti-
RhoA (sc-418; Santa Cruz Biotechnology). Films were digitized and densitometrically 
assessed. 
 
 
3.8 Co-precipitation assays with GST tagged recombinant proteins 
 
 Upon activation and / or under specific conditions, some proteins interact 
specifically with other proteins to initiate signaling pathway or to modulate molecular 
mechanisms. In order to investigate this protein-protein interaction and signal 
transduction at the BBB, co-precipitation assay was applied. Co-precipitation assay 
permits a quantitative analysis of protein-protein interactions, and offers a tool to 
study the interaction between two or more proteins especially when at least one of 
these proteins is present in very low quantity, which is compensated by adding 
exogenously this protein, by using recombinant proteins that are tagged glutathione 
S-transferase. For these experiments brain microvessel samples, equal protein 
quantities (600 µg) of lysates obtained using a MgCl2 lysis buffer containing 50 mM 
Tris base, 100 mM NaCl, 2 mM MgCl2 and 1% NP-40 (pH 7.4) were added in 
Eppendorf tubes and complemented to a total volume of 1 ml by adding MgCl2 lysis 
buffer.  
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Figure 14. Co-precipitation assay: GST-Bait is loaded into cell lysate samples, the 
proteins of interest bind the GST-Bait, which can be quantified and analyzed by 
Western blot. (Source: GE Healthcare, life science). 
 
 
 Co-precipitation with GST-Cdc42: To study the interaction between inactive 
Cdc42 with p120 catenin, 50 µl (50 µg) of recombinant GST-Cdc42-(T17N) (C17G01; 
Cytoskeleton Inc) prefixed on agarose beads were added to MgCl2 lysate samples, 
as described in the affinity binding assay protocol. Samples were subjected to SDS-
PAGE using 10% acrylamide-bis gel, followed by Western blot analysis, using anti-
p120 catenin (4989; Cell Signaling, Allschwil, Switzerland). 
 
 Co-precipitation with GST-RhoA: To investigate the upstream signalling 
pathway that contributed in RhoA activation, 50 µl (50 µg) of recombinant GST-
RhoA-(wildtype) (RHG01; Cytoskeleton Inc) prefixed on agarose beads were 
processed with MgCl2 lysate samples, as described in the affinity binding assay 
protocol. Samples were subjected to SDS-PAGE using 7% acrylamide-bis gel, 
followed by Western blot analysis for LARG (sc-25638; Santa Cruz Biotechnology). 
Films were digitized and densitometrically assessed. 
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3.9 Immunoprecipitation and co-immunoprecipitation assays 
 
To investigate intracellular signaling pathway, endogenous protein-protein 
interaction were studied. For this purpose immunoprecipitation and co-
immunoprecipitation assays were applied. As such, equal protein quantities (800 µg) 
of lysates obtained using a NP-40 lysis buffer containing 150 mM NaCl, 1% NP-40, 
50 mM Tris base (pH 8.0) were supplemented with sodium orthovanadate (final 
concentration: 1 mM) and complemented with three equal volumes of NET buffer 
(100 mM Tris, 200 mM NaCl, 5 mM EDTA, 5% NP-40, pH 7.4). Six µg of anti-RhoA 
antibody (sc-179, Santa Cruz Biotechnology), 2 µg of ApoER2 (sc-20746; Santa Cruz 
Biotechnology), 10 µg of occluding (sc-27151; Santa Cruz Biotechnology) or 6 µg of 
p-120 catenin (4989; Cell Signaling) were added to each sample, and incubated 
overnight at 4°C under slight rotation.  
 
The next day 20 µl of protein A/G plus-agarose (sc-2003; Santa Cruz 
Biotechnology) were added to the samples and incubated over one hour at 4°C. 
Finally samples were centrifuged for 30 seconds at 15,000 rpm at 4°C. Supernatants 
were dispersed and pellets washed three times in ice cold NET buffer. 20 µl of 2X 
SDS loading buffer was added to each pellet and boiled for 5 minutes (Heater Plate), 
followed by a short centrifugation at 4,000 rpm to precipitate beads.  
 
Supernatants were subjected to SDS-PAGE using 10% acrylamide-bis gel 
followed by Western blot analysis using anti-p120 catenin (4989; Cell Signaling), anti-
ZO-1 (40-2300; Invitrogen), anti-phospho-tyrosine (sc-508; Santa Cruz 
Biotechnology), phospho-threonine (sc-81527; Santa Cruz Biotechnology), anti-
phosphorylated JNK1/2Thr183/Tyr185 (9255; Cell Signaling), anti-JIP1/2 (34-5300; 
Invitrogen), anti-MKP-7 (sc-98872; Santa Cruz Biotechnology), anti-MKK-7 (4172; 
Cell Signaling) or anti-Vav2 (sc-20803). Films were digitized and densitometrically 
assessed. 
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3.10 Immunofluorescence staining 
 
In order to investigate the sub-cellular localization and co-localization of 
proteins expressed at the BBB, 20 µm thick cryostat brain sections obtained from 
were fixed in ice-cold acetone for 10 min, washed three times in 0.1M ice-cold 
phosphate-buffered saline (PBS), and blocked for 1 h in 0.1M PBS containing 0.25% 
Triton X-100 (PBS-T), 10% normal donkey serum (NDS) and 1% bovine serum 
albumin (BSA). After three more washes in 0.1M ice-cold PBS, sections were 
incubated overnight at 4°C with polyclonal rabbit a nti-ApoER2 (sc-20746; Santa Cruz 
Biotechnology) diluted to 1:50 in 0.1 M PBS-T and 2% Normal Donkey Serum (NDS), 
rat anti-CD31 (RM5200; Invitrogen, Karlsruhe, Germany) diluted to 1:200 in 0.1 M 
PBS-T and 2% NDS and mouse anti-GFAP-Alexa Fluor® 647 conjugated (3657, Cell 
Signaling). The next day sections were washed three times in ice-cold 0.1M PBS and 
incubated for 1 h with secondary donkey anti-rat-FITC (712-095-150; Jackson 
Immunoresearch, Suffolk, U.K.) and donkey anti-rabbit-TRITC (711-025-152; 
Jackson Immunoresearch), diluted 1:200 in 0.1M PBS-T and 2% NDS. Finally 
sections were mounted and coverslipped. Sections were microscopically evaluated 
and microphotographs taken from the ischemic striatum using confocal microscopy 
(Leica microsystems, Wetzlar, Germany). 
 
 
3.11 Caseinase microplate assay for calpain-1/2 
 
Calpain-1/2 enzyme are caseinase, therefore to investigate calpain-1/2’s role 
in LXR’s effects on the BBB, we developed a caseinase microplate assay, which 
evaluates caseinase activity in the presence of calpain-1/2’s endogenous inhibitors. 
Twenty µg of protein extracts from each sample, obtained using NP-40 lysis buffer 
containing 50 mM Tris-HCl, 150 mM NaCl and 1% NP-40 (pH 7.4), were added into 
96 well microplate and complemented with calibrating buffer containing 20 mM Tris-
HCl, 1 mM EDTA, 100 mM KCl and 0.1% 2-mercaptoethanol (pH 7.4), resulting in 
volumes of 60 µl in each well. 
 
 Two solutions were prepared containing casein at 20 µg / ml: (i) Solution A (= 
activation) consisted of 20 mM Tris-HCl, 1 mM EDTA, 10 mM Ca2+, 100 mM KCl and 
0.1% 2-mercaptoethanol (pH 7.4), allowing to study the enzymatic activity of caplain-
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1/2 owing to the fact that samples contained Ca2+ that is required for calpain-1/2 to 
exert its protease activity. (ii) Solution I (= inhibition) contained 20 mM Tris-HCl, 50 
mM EDTA, 100 mM KCl and 0.1% mercaptoethanol (pH 7.4). In this solution calpain-
1/2 was inactive as the sample lacked Ca2+ ions. Experiments were conducted in 
triplicate for each sample, 100 µl of solution A being added to the first set of wells 
containing protein samples, and 100 µl of solution I being added to the next set, 
increasing the total volume in each well to 160 µl (60 µl + 100 µl). As such, the assay 
was run four times for statistical comparisons.  
 
 Each microplate was incubated for 2 hours at room temperature. Then, 120 µl 
of 1X G-250 dye (Quick Start Bradford Protein Assay; Biorad) were added 
simultaneously to each well and incubated for 5 min at room temperature, the G-250 
dye forming a stable complex upon binding proteins shifting light absorbance from 
470 nm to 595 nm. The dye does not bind proteolytic fragments of digested proteins 
like small peptides or amino acids, assessing the enzymatic activity of calpain-1/2, 
the higher the activity the less absorbance values are.  
 
 The absorbance was read at 595nm using the iMark microplate reader and 
calpain-1/2 caseinase activity was calculated for each sample by subtracting 
absorbances between solution I and solution A. Calpain-1/2 protease activity was 
expressed as absorbance difference at 595 nm units (AD595nm). 
 
 
3.12 Gelatin polyacrylamide gel zymography for MMP-2/9 
 
MMP-2/9 enzyme are gelatinase, therefore to examine the role of MMP-2/9 in 
LXR’s actions on brain microvessels, we used both gelatin polyacrylamide gel 
zymography (Zechariah et al., 2010) and a gelatinase microplate assay, which we 
established in analogy to the caseinase microplate assay presented above. For 
polyacrylamide gel zymography, 25 µg proteins were mixed with 5X non reducing 
loading buffer for 15 min at room temperature and subjected to sodium 
dodecylsulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) using 9% 
acrylamide-bis gel containing 0.1% gelatin (Sigma). Gels were removed and washed, 
incubated for 1 hr at room temperature with slight shaking in modified enzymatic 
activation buffer (50 mM Tris-HCl, 6 mM CaCl2, 1.5 µM ZnCl2, pH 7.4) containing 
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2.5% Triton X-100 to remove SDS and restore gelatinase activity. Gels were then 
incubated for 24 hr at 37°C in modified enzymatic activation buffer. Gels were stained 
in Coomassie brilliant blue R-250 (Bio-Rad), followed by immersion in destaining 
solution (40% methanol, 10% acetic acid, 50% water) and 2% acetic acid. Gels were 
dried and digitized. A total of four experiments were run, which were 
densitometrically analyzed. 
 
 The limitation of gelatin zymography in our study is that the corresponding 
band of MMP-2 in stained gel is very fad and it is very hard to assess and quantify 
such band, therefore the gelatin zymography was adopted to study MMP-9 activity, 
and gelatinase microplate assay was adopted to study MMP-2 and MMP-9 activities. 
 
 
3.13 Gelatinase microplate assay for MMP-2/9 
 
For studying MMP-2/9 gelatinase activity in presence of their endogenous 
inhibitor, the gelatinase microplate assay was used. For this purpose the above 
caseinase microplate assay was adopted with the following changes: 5 µg of proteins 
obtained by using the same lysis buffer as above were added to a 96 well microplate, 
complemented with a calibrating buffer containing (50 mM Tris-HCl, 6 mM CaCl2, pH 
7.4) to have volumes of 60 µl in each well. Two solutions were prepared containing 
gelatin at a concentration of 20 µg/ml: (i) Solution A (= activation) (50 mM Tris-HCl, 6 
mM CaCl2, 1.5 µM ZnCl2, pH 7.4) and (ii) solution I (= inhibition) (50 mM Tris-HCl, 6 
mM CaCl2, 50 mM EDTA, pH 7.4), the two samples differing in terms of the presence 
and absence of ZnCl2, which is a co-factor needed for gelatinase to exert its 
enzymatic activity.  
 
 Experiments were again conducted in triplicate for each sample. The assay 
was run four times. Each microplate was incubated for 2 hours at 37°C. Then, G-250 
dye was added, the absorbance red, and MMP-2/9 gelatinase activity calculated by 
subtracting absorbance between solution I and solution A. MMP-2/9 protease activity 
was again expressed as absorbance difference at 595 nm units (AD595nm). 
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3.14 Reverse transcriptase (RT) - polymerase chain reaction (PCR) analysis 
 
To investigate the molecular mechanisms involved in regulating ABCB1 and 
ABCC1 at the transcriptional level at mice brain microvessels, we applied RT-PCR 
techniques to quantify mRNA of ABCB1 and ABCC1.  For this purpose, isolated brain 
microvessel samples were harvested in RNA stabilization reagent RNAlaterTM 
(Qiagen GmbH, Hilden, Germany). Total RNA was extracted using SV RNA-Isolation 
Kit (Promega GmbH, Mannheim, Germany) according to the manufacturer’s protocol. 
Total RNA purity and concentration were assessed using the NanoPhotometerTM 
system (Implen GmbH, Munich, Germany). Simultaneously, the expression of abcb1 
,abcc1 and the housekeeping gene succinate dehydrogenase complex subunit A 
(SDHA) were studied in individual animals using the one-step TaqMan® RT-PCR 
system with FAM-BHQ probe and ROX (passive reference) in 48 microplates 
(Applied Biosystems, Foster City, USA).  
 
For each sample, duplicates of 10 ng total RNA were processed in 15 µl 
volume reactions of the QTaq™ one-step qRT-PCR master mix kit (Clontech-Takara, 
Saint-Germain-en-Laye, France), which contains Hotstart Taq DNA polymerase and 
optimised reaction buffer with 5 mM MgCl2, 2.5-3.5 mM nucleotides (including 
dUTP), reverse transcriptase and RNAse inhibitor. NCBI GenBank Accession 
Number and primers used are shown in Supplementary Table 1. The PCR regime 
consists of a reverse transcriptase reaction (20 min at 48°C), followed by hotstart Taq 
DNA polymerase activation (10 min at 95°C), and fol lowed by 45 cycles (15 sec at 
95°C – 1 min at 60°C). The following primers were u sed: abcb1 (Genbank accession 
number: NM_011075.2) fwd: CACAGAAAGCAA GACCAAGAGA, rev: 
TTTAGATTTAGGATCCGCCAAA, TM: 5’FAM GCACATCTT CATCCACAGCCTCTT-
3’BHQ, abcc1 (Genbank accession number: NM_008576.2) fwd: 
GAACTTGGACCCTTTCAGTCAG, rev: GACACAAAGCCCTTTAGGTGAG TM: 
5’FAM-TCTGATGAAGAAGTCTGGAT GGCC-3’BHQ.For each gene in different 
samples, the delta threshold cycle (∆Cт) and delta-delta threshold cycle (∆∆Cт) 
values were calculated (∆Cт = Cт of the gene of interest - the Cт of SDHA; ∆∆Cт = 
∆Cт control – ∆Cт ischemic), followed by Fold Change calculation (Fold Change = 2 
(-1)*∆∆Cт gene of interest). 
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3.15 Enzyme-linked immunosorbent assay (ELISA) for FK506  
 
To translate the role of ApoE in controlling ABCB1 expression on brain drug 
accumulation, we performed pharmacological studies using FK506 (tacrolimus) which 
is a lipophilic compound and a well-known substrate of ABCB1. To investigate FK506 
accumulation and biodistribution in mice brain, we used PRO-TracTM II tacrolimus 
ELISA kit (Diasorin Deutschland GmbH, Dietzenbach, Germany) as described 
(Spudich et al., 2006). Briefly, whole blood samples were collected from mice heart in 
ethylene diamine tetraacetic acid (EDTA)-coated tubes. Weighted brain samples 
taken from the MCA territory both ipsilateral and contralateral to the stroke were 
harvested in ice cold normal saline solution (100 mg brain tissues in 1.5 ml normal 
saline solution). The PRO-TracTM II tacrolimus ELISA kit was only recommended for 
the analysis of FK506 in human blood, and the direct analysis of FK506 in mice brain 
homogenate failed probably due to the interfering mouse proteins, e.g. IgG.  
 
 Therefore FK506 has first to be extracted from mice brain homogenate 
(Yokogawa et al., 1999). For this purpose, brain homogenates and blood samples 
were pretreated with PRO-TracTM tacrolimus digestion reagent, and FK506 was 
extracted with n-hexane containing 2.5% isoamyl alcohol (1 volume homogenate: 9 
volumes n-hexane / 2.5% isoamyl alcohol). The extracted FK506 was diluted in PRO-
TracTM conjugate diluent and after competitive binding with FK506-horseradish 
peroxidase conjugate, substrate reaction was measured using iMark Microplate 
Reader (Bio-Rad) at 450/630 nm wavelength. Positive controls were provided in the 
ELISA kit, negative samples obtained from the brain and blood of untreated mice.  
 
Data were computed and concentrations calculated using 4PL curve fitting 
program (MPM6 software, Biorad). From the concentrations determined, brain-to-
blood concentration ratios were calculated and were expressed as ng.mg-1 (brain 
tissue) per µg.ml-1 (blood).  
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3.16 Statistics 
 
Results are presented as means ± S.D. Data were analyzed by unpaired t-
tests (comparisons between two groups) or one-way ANOVA followed by least 
significant differences (LSD) tests (comparisons between ≥4 groups) using SPSS for 
Windows. For the latter data, two-way ANOVA were also computed, of which 
condition interaction effects (mouse line x hemisphere or treatment x hemisphere) 
were reported in the graphs. In cases multiple comparisons were made (i.e., for 
ABCB1 and ABCC1), significance levels were adapted using Bonferroni corrections. 
P values less than 0.05 were considered significant. 
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4 RESULTS 
 
 
4.1 Part I: Effect of LXR activation on BBB tightness 
 
Liver X receptors (LXR) are sensors of cell metabolism. Their role in the 
maintenance of BBB tightness was unknown. In this study, mice receiving the LXR 
agonist T0901317 (1.25 mg, i.p.) or vehicle were submitted to transient focal cerebral 
ischemia. Twenty-four hours after reperfusion, ischemic injury, brain edema and 
serum IgG extravasation were assessed. Signaling pathways controlling BBB 
tightness were evaluated by Western blots, activity assays and protein interaction 
experiments.  
 
4.1.1 Effect of LXR activation on ischemic injury and vascular permeability 
 
To evaluate ischemia reproducibility, Laser Doppler flow (LDF) during and 
after MCA occlusion did not differ between vehicle treated and T0901317 treated 
animals. As such, LDF values decreased to 20.32±9% and 22.93±12% of baseline 
within 5 min after onset of ischemia in untreated and treated mice respectively, 
remaining stable throughout the MCA occlusion period. After reperfusion, LDF values 
rapidly recuperated to 82.5±17% and 86.4±18.8% of baseline.  
 
To evaluate effects of LXR activation on brain edema, vascular tightness and 
ischemic injury, we analyzed cresyl violet stainings and histochemistries against 
extravasated serum IgG. Reduced brain swelling (Figure 15A) and decreased serum 
IgG extravasation (Figure 15B) were noticed in ischemic animals receiving T0901317 
treatment, indicating preservation of the BBB by the LXR agonist. Infarct area did not 
show any difference between groups (Figure 15C). 
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Figure 15. LXR agonist decreases brain edema and leakage: Histochemical 
studies analyzing brain swelling (A) and serum IgG extravasation (B), which are both 
reduced in animals receiving the LXR agonist. Note that infarct area (C) is not 
influenced by LXR activation. Western blots using brain capillary extracts show that 
T0901317 robustly increases LXRαβ expression (D). Data are means ± SD (n=4 
Western blots). C, contralateral non-ischemic microvessels; I, ischemic microvessels. 
*p<0.05/**p<0.01 compared with non-ischemic vehicle (A, B, C: unpaired two-tailed t-
tests, D: one-way analysis of variance (ANOVA) followed by LSD tests) 
A B 
C D 
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4.1.2 Effect of T0901317 on LXRαβ expression  
 
LXR activation by T0901317 potently increases LXRαβ expression (Whitney et 
al., 2001). To verify T0901317 administration efficacy, we checked LXRαβ levels in 
brain microvessels using Western blot analysis. We showed that LXRαβ expression 
is indeed increased by T0901317 in both the ischemic and non-ischemic brain tissue 
(Figure 15D). 
 
4.1.3 Calpain-1/2 and MMP-2/9 activities regulation after LXR activation 
 
To elucidate the role of calpain-1/2 and MMP-2/9 in BBB preservation induced 
by LXR activation, we evaluated their expression and activity in cerebral 
microvessels by Western blots, calpain-1/2 caseinase microplate assay, gelatine 
zymography and MMP-2/9 gelatinase microplate assay. Western blots revealed that 
the overall expression of calpain-1/2 and MMP-2/9 is neither influenced by ischemia 
nor by T0901317 (Figure 16A).  
The activities of calpain-1/2 and MMP-2/9, on the other hand, strongly 
increased after stroke (Figure 16B-D), which is in line with earlier studies from other 
groups (Cao et al., 2007; Zhao et al., 2006; Tsubokawa et al., 2006). Importantly, 
calpain-1/2 and MMP-2/9 activities were attenuated by LXR agonist (Figure 16B-D). 
In case of MMP-2 and -9, inhibition of protease activity was detected by using 
gelatine zymography and MMP-2/9 gelatinase microplate assay (Figure 16C,D) that 
evaluate MMP-2/9 activity in the absence and presence of endogenous inhibitors, 
which, based on our studies, are not essential for LXR’s inhibitory influence on MMP-
2/9.   
 
4.1.4 T0901317 increases the expression of LXR’s target gene calpastatin 
 
To identify factors responsible of calpain-1/2 deactivation, we studied the 
expression of its specific inhibitor calpastatin, which is transcriptionally regulated by 
LXR (Hummasti et al., 2004), by means of Western blots. Reduced expression levels 
of calpastatin were observed in ischemic microvessels of vehicle-treated mice (Figure 
17A). T0901317 increased calpastatin expression above levels in non-ischemic 
vessels (Figure 17A). Our data suggest that calpastatin is responsible for the 
inhibition of calpain-1/2 by the LXR agonist.  
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Figure 16. LXR agonist decreases calpain-1/2 and MMP-2/9 activities: Western 
blots (A,), calpain-1/2 caseinase assay (B), MMP-9 gelatine zymography (C), and 
MMP-2/9 gelatinase assay (D) showing that calpain-1/2 and MMP-2/9 activity (B-D) 
but not expression (A) are reduced in ischemic microvessels of T0901317 treated 
mice. Data are means ± SD (n=4 Western blots or assays). C, contralateral non-
ischemic microvessels; I, ischemic microvessels. *p<0.05/**p<0.01 compared with 
non-ischemic vehicle/ †p<0.05/††p<0.01 compared with ischemic vehicle (one-way 
analysis of variance (ANOVA) followed by LSD tests). 
A B 
C D 
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4.1.5 LXR activation stabilizes p120 catenin 
 
To define downstream targets of calpain-1/2 that might mediate BBB 
preservation induced by LXR activation, we assessed the expression of p120 
catenin, a target protein degraded by calpain-1/2 (Ohno et al., 2007), using Western 
blot analysis. As a consequence of calpain-1/2 activation, p120 catenin expression 
was reduced in ischemic microvessels of vehicle-treated mice (Figure 17B). 
Conversely, treatment with T0901317 that inhibited calpain-1/2 elevated p120 
catenin expression in ischemic brain capillaries even above levels in non-ischemic 
vessels (Figure 17B). 
 
 
 
 
 
 
 
Figure 17. LXR agonist induces calpastatin expression, stabilizing p120 
catenin: Western blots (A, B) show calpain-1/2 endogenous inhibitor calpastatin is 
overexpressed in the presence of the LXR agonist (A). In response to the reduced 
activity of calpain-1/2, p120 catenin expression is preserved (B). Data are means ± 
SD (n=4 Western blots or assays). C, contralateral non-ischemic microvessels; I, 
ischemic microvessels. *p<0.05/**p<0.01 compared with non-ischemic vehicle/ 
†p<0.05/††p<0.01 compared with ischemic vehicle (one-way analysis of variance 
(ANOVA) followed by LSD tests). 
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4.1.6 LXR activation differentially regulates RhoA and Cdc42 activation 
 
To understand whether and how LXR activation influences the activity of Rho 
GTPases involved in the regulation of BBB tightness, we next performed pulldown 
assays for RhoA and Cdc42. These studies revealed that both RhoA and Cdc42 are 
activated upon ischemia in cerebral microvessels (Figure 18A, B). Interestingly, 
T0901317 treatment inhibited RhoA (Figure 18A), at the same time further elevating 
Cdc42 activity in ischemic, but not in non-ischemic vessels (Figure 18B).  
 
4.1.7 Differential regulation of RhoA and Cdc42 activity in ischemic 
microvessels 
  
Since p120 catenin acts as GDI for RhoA (Wildenberg et al., 2006; 
Anastasiadis et al., 2000) and also binds GEFs that specifically activate Cdc42 
(Noren et al., 2000), we investigated the role of p120 catenin in the differential 
regulation of RhoA and Cdc42 by T0901317.  
 
In immunoprecipitation studies we showed that RhoA binds physically to p120 
catenin in vehicle treated, non-ischemic cerebral microvessels, whereas this RhoA 
interaction with p120 catenin is absent in ischemic brain capillaries (Figure 18C). 
T0901317 restored the RhoA binding to p120 catenin in ischemic microvessels 
(Figure 18C), indicating that RhoA interaction with this GDI is responsible for the 
RhoA inhibition by the LXR agonist.  
 
On the other hand, we found that inactive GST-Cdc42 binds p120 catenin in 
T0901317 treated, but not in vehicle treated non-ischemic and ischemic microvessels 
(Figure 18D), most likely as a result of the p120 catenin expression loss.  Active 
GST-Cdc42 did not reveal interaction with p120 catenin (not shown). Moreover, we 
observed that Vav2 interacts with p120 catenin (Figure 18D), suggesting that p120 
catenin promotes Cdc42 activation by enhancing the access of Cdc42 to its GEF.  
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Figure 18. p120 catenin controls RhoA and Cdc42 activation: Pull-Down assays 
detecting GTP-bound (i.e., activated) RhoA and Cdc42 reveal that LXR induction 
reduces RhoA activation (A) and increases Cdc42 activation (B) in ischemic 
microvessels. Western blots of total RhoA and Cdc42 expression reveal no 
differences among groups (A, B). Immunoprecipitation experiments demonstrate that 
RhoA binding to p120 catenin is abolished upon ischemia, but restored upon 
T0901317 treatment (C). Co-precipitation studies show that inactive Cdc42 does not 
bind p120 catenin neither under normal, nor ischemic microvessels of vehicle-treated 
mice (D). Interestingly, LXR activation induces binding of inactive Cdc42 to p120 
catenin, which also binds Vav2, a Cdc42 GEF (D). Data are means ± SD (n=4 
pulldown assays). C, contralateral non-ischemic microvessels; I, ischemic 
microvessels. *p<0.05/**p<0.01 compared with non-ischemic vehicle/ †p<0.05 
compared with ischemic vehicle (one-way analysis of variance (ANOVA) followed by 
LSD tests). 
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4.1.8 Regulation of occludin and ZO-1 after LXR activation 
 
To further elucidate how LXR activation influences BBB integrity, we studied 
the expression, phosphorylation and interaction of the tight junction proteins occludin 
and ZO-1 by Western blots and immunoprecipitation studies. In accordance to 
previous studies (Takenaga et al., 2009; Chen et al., 2000), the overall expression 
and threonine phosphorylation of occludin decreased, the tyrosine phosphorylation of 
occludin increased and the association of occludin with ZO-1 decreased upon 
ischemia in vehicle treated microvessels (Figure 19A, B; Figure 20A, B), reflecting 
the breakdown of BBB integrity following stroke. Interestingly, T0901317 selectively 
increased occludin and ZO-1 expression on ischemic microvessels (Figure 19A, B), 
at the same time reversing occludin threonine phosphorylation and abolishing 
occludin tyrosine phosphorylation, thus enhancing the assembly of occludin with ZO-
1 (Figure 20A, B).  
 
 
 
 
Figure 19. LXR activation modulates the expression of occludin and ZO-1: 
Western blot analysis (A, B) demonstrating that T0901317 restores occludin and ZO-
1 expression in ischemic microvessels that are otherwise reduced in vehicle treated 
mice (A, B). Data are means ± SD (n=4 Western blots). C, contralateral non-ischemic 
microvessels; I, ischemic microvessels. *p<0.05/**p<0.01 compared with non-
ischemic vehicle/ ††p<0.01 compared with ischemic vehicle (one-way analysis of 
variance (ANOVA) followed by LSD tests). 
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Figure 20. LXR activation modulates the phosphorylation of occludin, and its 
assembly with ZO-1: Immunoprecipitation experiments (C, D) demonstrating that 
T0901317 decreases occludin tyrosine phosphorylation (C), increasing occludin 
threonine phosphorylation (C) and enhancing occludin interaction with ZO-1 (D). 
Data are means ± SD (n=4 Western blots). C, contralateral non-ischemic 
microvessels; I, ischemic microvessels. *p<0.05/**p<0.01 compared with non-
ischemic vehicle/ ††p<0.01 compared with ischemic vehicle (one-way analysis of 
variance (ANOVA) followed by LSD tests). 
 
 
4.1.9 LXR activation deactivates JNK1/2 pathways and caspase-3  
 
The activation of Jun N-terminal kinase-1/2 (JNK-1/2) via phosphorylation 
represents a cellular stress signal that promotes endothelial apoptosis (Schulz et al., 
2008). To analyze how LXR activation influences JNK1/2 phosphorylation state, we 
performed Western blots using antibodies detecting either phosphorylated or total 
(i.e., phosphorylated and unphosphorylated) JNK1/2. In vehicle treated mice, JNK 
phosphorylation was decreased in ischemic microvessels (Figure 21A). T0901317 
further reduced JNK1/2 phosphorylation levels (Figure 21A). It has been shown that 
calpain-1/2 facilitates the activation of caspase-3, thus promoting neuronal apoptotic 
injury (Blomgren et al., 2001). To investigate how T0901317, which deactivates 
calpain-1/2, influences caspase-3 activity, we examined the expression of cleaved, 
i.e., activated caspase-3 by Western blots. Our results showed that caspase-3, which 
is strongly activated upon ischemia, is deactivated by LXR agonist (Figure 21B). Our 
data point towards a survival-promoting effect of T0901317 on cerebral microvessels.  
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Figure 21. LXR agonist deactivates JNK1/2 and caspase-3: Western blot analysis 
shows that LXR activation decreases JNK phosphorylation (A) and caspase-3 
cleavage (B) in ischemic microvessels. Data are means ± SD (n=4 Western blots). C, 
contralateral non-ischemic microvessels; I, ischemic microvessels. *p<0.05/**p<0.01 
compared with non-ischemic vehicle/ †p<0.05 compared with ischemic vehicle (one-
way analysis of variance (ANOVA) followed by LSD tests). 
 
 
4.1.10 T0901317 regulates ABC transporters at the BBB, without influencing 
their polarity 
 
We have previously shown that the ABC transporter ABCB1 is upregulated on 
the luminal surface (Spudich et al., 2006), whereas ABCC1 is downregulated on the 
abluminal surface of ischemic endothelial cells (Kilic et al., 2008), presumably as part 
of endogenous attempt protecting the brain against blood-derived toxins. By means 
of Western blots we now observed that the lipid transporters ABCA1 and ABCG1, 
known LXR targets (Naik et al., 2006), are upregulated on cerebral microvessels 
upon T0901317 treatment (Figure 22A, B). Strikingly, LXR activation also elevated 
ABCB1 expression (Figure 22C) and restored the reduced ABCC1 expression that 
was observed in ischemic vehicle treated mice (Figure 22D). As such, there was an 
overall upregulation pattern of ABC transporters – both of luminally located and 
abluminal ones – by LXR activation, which did not affect the polarity of the 
transporters. We interpret the elevated ABC transporters levels as a part of 
mechanism strengthening neurovascular integrity. 
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Figure 22. LXR activation upregulates ABC transporters: Western blot analysis 
revealing that the LXR agonist increases expression levels of the lipid transporters 
ABCA1 (A) and ABCG1 (B) on brain microvessels, at the same time elevating 
expression levels of the drug transporters ABCB1 (C) and ABCC1 (D) on ischemic 
capillaries. Data are means ± SD (n=4 Western blots). C, contralateral non-ischemic 
microvessels; I, ischemic microvessels. *p<0.05/**p<0.01 compared with non-
ischemic vehicle/ †p<0.05/††p<0.01 compared with ischemic vehicle (one-way 
analysis of variance (ANOVA) followed by LSD tests). 
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4.2 Part II: Effect of apolipoprotein-E (ApoE) on BBB polarity 
 
By means of protein and gene expression studies that we combined with 
genetic knockout, pharmacological and protein delivery experiments, we investigated 
the role of ApoE in the regulation of BBB polarity, studying the post-ischemic 
expression of ABCB1 and ABCC1 and examining drug accumulation in the ischemic 
brain.  
 
 
4.2.1 Severity of injury does not differ between wildtype and ApoE-/- mice 
 
Laser Doppler flow (LDF) during and after MCA occlusion did not differ 
between wildtype and ApoE-/- animals that were held on normal diet. As such, LDF 
values decreased to 20.2±5.2% and 21.4±4.1% of baseline within 5 min after onset of 
ischemia in C57BL6/j and ApoE-/- mice, remaining stable throughout the MCA 
occlusion period. After reperfusion, LDF values rapidly recuperated to 87.2±15.5% 
and 89.0±12.1% of baseline. Twenty-four hours after the stroke, localized brain 
lesions were observed in the mouse striatum. Infarct areas at the level of the mid-
striatum were similar in both mouse lines (4.30±0.51 vs. 4.21±0.47 mm2). 
 
4.2.2 ABCB1 and ABCC1 are inversely regulated upon ischemia in wildtype and 
ApoE-/- mice 
 
To study ABC transporters expression, we used brain microvascular extracts, 
which did not reveal any GFAP protein expression (Figure 23A), indicating absence 
of astrocytic endfeet in these samples. Importantly, ABCB1, which is upregulated on 
ischemic cerebral microvessels of wildtype mice (Spudich et al., 2006), was 
downregulated (Figure 23B), whereas ABCC1, which is expressed at reduced level 
on ischemic brain capillaries of wildtype mice (Kilic et al., 2008), was overexpressed 
upon ischemia in ApoE-/- animals (Figure 23C). Real time-polymerase chain reaction 
analysis (RT-PCR) demonstrated that abcb1 mRNA was upregulated upon stroke in 
wildtype, but not ApoE-/- mice, whereas abcc1 mRNA was elevated after ischemia in 
ApoE-/- but not wildtype mice (Figure 23D), thus confirming differential expression of 
both ABC transporters on the transcriptional level. 
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Figure 23.  ABC transporters are inversely regulated upon ischemia in the 
presence and absence of ApoE: Western blot analysis using brain capillary 
extracts showing that (A) GFAP is expressed neither in non-ischemic nor in ischemic 
microvessels of wildtype mice and ApoE-/-, and (B) ABCB1, which is upregulated in 
wildtype animals, is downregulated, whereas (C) ABCC1, which is expressed at 
reduced level in wildtype mice, is overexpressed following stroke in ApoE-/- mice. RT-
PCR studies reveal that (D) abcb1 mRNA expression is induced in the ischemic 
cerebral microvessels of wildtype but not ApoE-/- mice, whereas abcc1 mRNA is 
reduced in ApoE-/- but not wildtype mice. Data are means ± SD (n = 4 separately 
processed Western blots/ RT-PCR). C, contralateral non-ischemic microvessels; I, 
ischemic microvessels. *p< 0.05 / **p< 0.01 compared with non-ischemic wildtype // 
††p< 0.01 compared with non-ischemic ApoE-/- (B, C: one-way analysis of variance 
(ANOVA) followed by LSD tests; two-way ANOVA were also computed, from which 
mouse line x hemisphere interaction effects are shown; D: unpaired two-tailed t-
tests). 
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4.2.3 ApoE and its receptor, ApoE receptor-2 (ApoER2), are present on 
ischemic brain capillaries 
 
To evaluate whether ApoE is present in cerebral microvessels, Western blots 
and immunohistochemistry were used. These studies revealed that ApoE is de novo 
present on ischemic brain capillaries (Figure 24A) together with its receptor ApoER2, 
which is constitutively expressed on microvascular cells of wildtype and ApoE-/- mice, 
namely on the abluminal endothelial surface, in between the CD31+ luminal 
endothelial surface and GFAP+ astrocytic endfeet  (Figure 24B).  
 
 
 
 
 
 
 
 
 
 
Figure 24. ApoE and its receptor ApoER2 are expressed on cerebral 
microvessels: Western blotting (A) and immunohistochemical (B) analysis 
examining the presence and absence of ApoE and ApoER2 in mouse cerebral 
capillary extracts. In wildtype mice, ApoE appears on cerebral microvessels after 
MCA occlusion together with its receptor ApoER2 (A), which is constitutively 
expressed on endothelial cells, particularly on their abluminal surface, i.e. in between 
the luminal CD31+ endothelial membrane and GFAP+ astrocytic endfeet (B). C, 
contralateral non-ischemic microvessels; I, ischemic microvessels. Bar, 15 µm. 
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4.2.4 ApoER2 binds Jun kinase-1/2 (JNK1/2), its kinase and phosphatase via 
JNK1/2-interacting protein-1/2 (JIP1/2) 
 
ApoER2 has previously been demonstrated to form complexes with Jun N-
terminal kinase-1/2 (JNK1/2)-interacting protein-1/2 (JIP1/2) in rat total brain extracts 
(Verhey et al., 2001; Stockinger et al., 2001). To assess whether ApoER2 also binds 
JIP1/2 in brain capillaries, co-immunoprecipitation studies were performed. These 
experiments revealed that ApoER2 indeed forms complexes with JIP1/2, furthermore 
binding JNK1/2 (Figure 25A), JNK1/2’s kinase mitogen-activated protein kinase 
(MAPK) kinase-7 (MKK7) and JNK1/2’s phosphatase MAPK phosphatase-7 (MKP7) 
(Figure 25B). 
 
 
 
 
 
 
 
Figure 25. ApoER2 signaling complex at the cerebral microvessels: Western 
blotting (C, D), and co-immunoprecipitation (C, D) analysis examining the expression 
of JIP-1/2 (C,D) and the interaction of ApoER2 with JIP1/2, phosphorylated JNK1/2, 
MKP-7 and MKK-7 in mouse cerebral capillary extracts. ApoER2 constitutively forms 
a complex with JIP1/2 (C, D), furthermore binding JNK1/2 (C), its kinase MKK7 and 
phosphatase MKP7 (D) in ApoE-/- and wildtype cerebral capillary extracts. C, 
contralateral non-ischemic microvessels; I, ischemic microvessels.  
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4.2.5 ApoE-/- abolishes post-ischemic deactivation of JNK1/2, thereby 
overactivating c-Jun  
 
To examine whether the presence or absence of ApoE affects the 
phosphorylation (i.e activation) of JNK1/2 and its downstream signal, the transcription 
factor c-Jun using Western blots were used. These studies revealed that in the 
presence of ApoE, levels of phosphorylated JNK1/2 were reduced in ischemic 
microvessels (Figure 26A). As a consequence, levels of phosphorylated (i.e. 
activation) c-Jun were low, indicating that the transcription factor was inactive (Figure 
26B). In the absence of ApoE, levels of phosphorylated JNK1/2 increased (Figure 
26A), which went along with increased phosphorylation, i.e., overactivation of c-Jun 
(Figure 26B). 
 
 
 
 
 
Figure 26. ApoE depletion abolishes post-ischemic deactivation of JNK1/2, 
thereby overactivating the transcription factor c-Jun: Western blot analysis 
shows that in the presence of ApoE, phosphorylated JNK1/2 is reduced (A) and 
phosphorylated c-Jun is low (B). In the absence of ApoE, levels of phosphorylated 
JNK1/2 increase (A), which goes along with elevated phosphorylation of c-Jun (B). 
Data are means ± SD (n = 4 separately processed Western blots). C, contralateral 
non-ischemic microvessels; I, ischemic microvessels. *p< 0.05 / **p< 0.01 compared 
with non-ischemic wildtype // ††p< 0.01 compared with non-ischemic ApoE-/- (one-
way analysis of variance (ANOVA) followed by LSD tests; two-way ANOVA were also 
computed, from which mouse line x hemisphere interaction effects are shown). 
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4.2.6 Delivery of recombinant human ApoEε3 or of JNK1/2 inhibitor restores 
ABC transporter levels 
 
To test whether ApoE is indeed responsible for the coordinated expression 
changes of ABCB1 and ABCC1 after stroke, mice submitted to 30 min MCA 
occlusion were intraperitoneally treated either with recombinant human ApoEε3 (50 
µg) or with the pharmacological JNK1/2 pathway inhibitor SP600125 (1.25 mg). 
Indeed, both recombinant human ApoEε3 and SP600125 attenuated the 
phosphorylation of JNK1/2 (Figure 27A) and c-Jun (Figure 27B) induced by ApoE-/- 
and restored ABCB1 (Figure 28A) and ABCC1 (Figure 287B) levels. These studies 
confirmed that ApoE regulates both ABC transporters in the ischemic brain. 
 
 
 
 
 
 
Figure 27. Recombinant human ApoEε3 and pharmacological JNK1/2 blockade 
restore JNK1/2 activation: Intraperitoneal delivery of recombinant human ApoEε3 
(50 µg) or of the JNK1/2 pathway inhibitor SP600125 (1.25 mg) to ApoE-/- mice 
attenuates the post-ischemic phosphorylation (i.e., activity) of JNK1/2 (A) and c-Jun 
(B), C, contralateral non-ischemic microvessels; I, ischemic microvessels; S, serum. 
*p< 0.05 / **p< 0.01 compared with non-ischemic ApoE-/- // ‡p< 0.05 / ‡‡p< 0.01 
compared with ischemic ApoE-/- (one-way ANOVA followed by LSD tests; treatment x 
hemisphere interaction effects from two-way ANOVA are also shown). 
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Figure 28. Recombinant human ApoEε3 and pharmacological JNK1/2 blockade 
restore ABC transporters expression: Intraperitoneal delivery of recombinant 
human ApoEε3 (50 µg) or of the JNK1/2 pathway inhibitor SP600125 (1.25 mg) to 
ApoE-/- mice replenishes ABCB1 (C) and mitigating ABCC1 (D) levels. These data 
show that ApoE controls ABC transporter expression in a JNK1/2-dependent way. 
Data are means ± SD (n = 4 Western blots). C, contralateral non-ischemic 
microvessels; I, ischemic microvessels; S, serum. *p< 0.05 / **p< 0.01 compared with 
non-ischemic ApoE-/- // ‡p< 0.05 / ‡‡p< 0.01 compared with ischemic ApoE-/- (one-
way ANOVA followed by LSD tests; treatment x hemisphere interaction effects from 
two-way ANOVA are also shown). 
 
 
4.2.7 ApoE deficiency enhances FK506 accumulation in ischemic brain, 
whereas ApoE delivery partly restores drug elimination 
 
To evaluate whether the downregulation of ABCB1 in ApoE-/- mice increases 
the brain passage of FK506 (tacrolimus), a well-known ABCB1 substrate, enzyme-
linked immunosorbent assays (ELISA) (Spudich et al., 2006) were used. Whole blood 
FK506 concentrations were very similar in wildtype and ApoE-/- mice, both when 
vehicle and recombinant human ApoEε3 were delivered (Figure 29A). Importantly, 
ApoE-/- increased the brain-to-blood concentration ratio of FK506 in the ischemic 
tissue by more than five times (Figure 29B). Conversely, recombinant human ApoEε3 
delivery reduced the brain uptake (Figure 29B). Our data demonstrate that by 
regulating ABC transporter levels, ApoE controls drug accumulation in the ischemic 
brain. 
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Figure 29. ApoE depletion enhances ABCB1 substrate (FK506) accumulation in 
the ischemic brain that is partly reversed by human ApoEε3: ELISA for the 
ABCB1 substrate FK506 showing no difference of FK506 levels in whole blood 
samples of vehicle treated wildtype mice, vehicle treated ApoE-/- mice and 
recombinant human ApoEε3 treated ApoE-/- mice (A). Interestingly, ApoE-/- increases 
brain FK506 levels in the ischemic, but not non-ischemic MCA territory by more than 
five times (B). This elevation is attenuated by recombinant human ApoEε3 (B). Data 
are means ± SD (n = 5 animals per group). C, contralateral hemisphere; I, ischemic 
hemisphere. **p< 0.01 compared with ischemic wildtype // ‡p< 0.05 compared with 
ischemic ApoE-/- (one-way ANOVA followed by LSD tests; treatment x hemisphere 
interaction effects from two-way ANOVA are also shown). 
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4.3 Part III: Effect of hypercholesterolemia on the ischemic BBB 
 
To elucidate the effect of hypercholesterolemia on BBB tightness and polarity 
after stroke, we subjected C57Bl6/j mice fed with regular (i.e., normal) diet or 
cholesterol-rich (so-called Western) diet to 30 min MCA occlusion. Using protein 
expression, interaction studies and enzymatic activity assays, we investigated the 
effect of hypercholesterolemia on ischemic injury, brain edema and BBB function. 
 
 
4.3.1 Increased brain swelling and IgG extravasation in animals receiving 
cholesterol-rich (Western) diet 
 
To evaluate the reproducibility of ischemia, LDF measurements were 
analyzed. LDF values decreased to 20.32±9% and 18.1±10% of baseline within 5 
min after onset of ischemia in animals receiving normal and Western diet, remaining 
stable throughout the MCA occlusion period. After reperfusion, LDF values rapidly 
recuperated to 82.5±17% and 91±21 of baseline.  
 
Twenty four hours after reperfusion, focal ischemic injury was observed after 
animal sacrifice mainly in the striatum. As such, mild brain edema (Figure 30A) 
associated with modest IgG extravasation (Figure 30B) was noticed in animals on 
normal diet. Western diet markedly increased brain swelling and IgG extravasation 
(Figure 30A, B). Interestingly Infarct areas did not differ between groups (Figure 
30C). 
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Figure 30. BBB permeability is increased in hypercholesterolemic mice 
submitted to MCA occlusion: Brain edema (A), serum IgG extravasation (B), and 
infarct area (C) measured at the level of the midstriatum 24 hours after reperfusion in 
wildtype mice receiving regular (i.e., normal) or cholesterol-rich (i.e., Western) diet. 
Note the absence of infarct area (C) changes in Western diet mice. Data are means ± 
SD (n = 6 animals per group). **p< 0.01 compared with normal diet (unpaired two-
tailed t-tests). 
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4.3.2 Overactivation of calpain-1/2 and MMP-2/9 in ischemic microvessels of 
hypercholesterolemic mice 
 
To elucidate the effects of hypercholesterolemia on calpain-1/2 and MMP-2/9 
activity, which contribute to BBB breakdown (Chaitanya and Babu, 2008; Kamada et 
al., 2007), microplate assays and gelatine zymography were used. Calpain-1/2 and 
MMP-2/9 activities did not differ between groups in non-ischemic tissues (Figure 
31A). Upon ischemia, calpain-1/2 protease activity increased in cerebral 
microvessels of normal diet mice (Figure 31A). This activation was augmented by the 
Western diet (Figure 31A).  
 
Since the microplate assay evaluates protease activity in the presence of 
endogenous inhibitors, we checked the expression of calpain-1/2’s endogenous 
inhibitor calpastatin by Western blots. Thus, calpastatin was downregulated by 
ischemia, more strongly in animals receiving Western than normal diet (Figure 31B), 
thus providing an explanation for the overactivation of calpain-1/2.  
 
It has been shown that MMP-9 activity is negatively regulated by calpain-1/2 
inhibitors (Tsubokawa et al., 2006), suggesting that calpains mediate, at least partly, 
MMPs activation. Therefore in addition to calpian-1/2, the activation of MMP-2/9 was 
investigated using gel zymography and gelatinas microplate assays. Similarly to 
calpain-1/2, MMP-2/9 activity was increased in ischemic microvessels, as shown in 
gel zymography (Figure 31C) and microplate assay (Figure 31D), more strongly in 
animals receiving Western than normal diet. Our data suggest that both MMP-2/9 
and calpain-1/2 may contribute to the elevated BBB permeability induced by 
hypercholesterolemia.  
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Figure 31. Calpain-1/2 and MMP-2/9 activities are elevated in cerebral 
microvessels of ischemic mice receiving cholesterol-rich diet: Caseinase 
microplate assay for calpain-1/2 (A), Western blot for calpain-1/2's endogenous 
inhibitor calpastatin (B), gelatine gel zymography for MMP-9 (C) and gelatinase 
microplate assay for MMP-2/9 (D) using brain capillary extracts from mice submitted 
to MCA occlusion. Note that in parallel with the activation of calpain-1/2 (A) and 
MMP-2/9 (C, D) calpain-1/2's endogenous inhibitor calpastatin, which is 
downregulated by Western diet. Data are means ± SD (n = 4 assays, zymographies 
or blots per group). C, contralateral non-ischemic; I, ischemic. *p< 0.05 / **p< 0.01 
compared with corresponding non-ischemic/ †p< 0.05 / ††p< 0.01 compared with 
ischemic normal diet (one-way analysis of variance (ANOVA) followed by LSD tests). 
A B 
C D 
 77 
4.3.3 Cholesterol-rich diet enhances the activation of RhoA and downregulates 
tight junction protein occludin 
 
RhoA is a member of the Rho GTPases proteins family that has previously 
been shown to destabilize tight junctions, thus promoting BBB breakdown (van 
Nieuw Amerongen et al., 2000; Schreibelt et al., 2007). To elucidate whether RhoA is 
responsible for the induction of BBB permeability by hypercholesterolemia, we used 
Western blots, pull-down assay experiments. Western blots analysis showed that ZO-
1 expression was not altered in response to stroke, neither under conditions of 
normal nor Western diet (Figure 32A). On the other hand, the expression of occludin 
decreased upon ischemia in cerebral microvessels of normocholesterolemic mice 
(Figure 32A). Hypercholesterolemia further reduced occludin expression (Figure 
32A). Using pull-down assays, we showed that RhoA activity increased upon 
ischemia in brain microvessels of normocholesterolemic mice (Figure 32B). Western 
diet further increased RhoA activation (Figure 32B).  
 
 
 
 
 
 
Figure 32. Western diet activates RhoA, resulting in tight junction protein 
occludin downregulation: Western blots for the tight junction proteins occludin and 
zona occludens (ZO)-1 (A). Western blots and pull-down assay for RhoA (B). Data 
are means ± SD (n = 4 Western blots, pull-down assays). C, contralateral non-
ischemic; I, ischemic. *p< 0.05 / **p< 0.01 compared with corresponding non-
ischemic/ †p< 0.05 compared with ischemic normal diet (one-way analysis of 
variance (ANOVA) followed by LSD tests). 
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4.3.4 Angiotensin II type 1 receptor (AT1R) upregulation in cholesterol-rich diet 
enhances the activation of RhoA in ischemic brain microvessels  
 
 To investigate part of the upstream signaling pathways that contributes in 
RhoA activation, Western blots and co-precipitation experiments were used. 
Angiotensin II type 1 receptor (AT1R) activation by angiotensin II induces 
vasoconstriction in many vascular systems by at leats partly induicing RhoA 
activation (Ito et al., 1991). It has been shown that hypercholesterolemia and 
hypertension increase the expression of AT1R, leading to endothelial cell wall 
dysfunction (Watanabe et al., 2005). Using Western blot analysis, we show here that 
ischemic stroke did not influence AT1R expression, whereas the expression of AT1R 
has increased in ischemic cerebral microvessels of hypercholesterolemic mice 
(Figure 33A).  
 
Moreover, AT1R has been shown to induce RhoA activation by directly 
enhancing RhoA access and activation by its GEF, leukemia associated Rho-GEF 
LARG (Ying et al., 2006). Western blots analysis show an increased expression of 
LARG in ischemic cerebral microvessels of hypercholesterolemic mice (Figure 33B). 
Using co-precipitation experiments with glutathione-S-transferase tagged wildtype 
RhoA (GST-RhoA), showed an enhanced interaction between RhoA and LARG 
(Figure 33C) in ischemic cerebral microvessels of hypercholesterolemic mice, 
providing a link between AT1R upregulation and RhoA overactivation upon stroke 
under hypercholesterolemia conditions.   
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Figure 33. AT1R is upregulated in Western diet, overactivating RhoA through 
its GEF, LARG: Western blot for AT1R (A), Western blot for LARG (B), co-
precipitation study exhibiting interaction of RhoA and LARG following Western diet 
(C). Data are means ± SD (n = 4 Western blots and co-precipitation studies per 
group). C, contralateral non-ischemic; I, ischemic. *p< 0.05 / **p< 0.01 compared with 
corresponding non-ischemic/ †p< 0.05 compared with ischemic normal diet (one-way 
analysis of variance (ANOVA) followed by LSD tests). 
B C 
A 
 80 
4.3.5 Hypercholesteroleia does not influence ABC transporter expression  
 
 Many ABC transporters play an important role in the transport of lipids. ABC 
transporters regulation at the BBB by lipid serum levels remains unclear. Besides the 
drug transporters ABCB1 and ABCC1, we investigated the expression of two 
important lipid transporters ABCA1 and ABCG1 at the BBB. By using Western blot 
analysis, we showed that the expression of ABCA1, ABCG1, ABCB1 and ABCC1 is 
similar in the ischemic microvessels of normal and hypercholesterolemic mice (not 
shown). This result shows that BBB polarity upon stroke is not influenced by 
hypercholesterolemia. 
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5 DISCUSSION 
 
 
5.1 General aspects 
 
 BBB tightness and polarity are crucial for a proper function of the CNS. We 
show in this study that BBB tightness and polarity both respond to ischemic stroke, 
and that both features are differentially regulated on the molecular level. As such, the 
molecular mechanisms involved in controlling BBB tightness do not regulate BBB 
polarity and vice versa. As such, protecting the tightness of the BBB offers new 
approaches in limiting incidence and severity of many cerebrovascular diseases, 
such as stroke, and controlling BBB polarity may allow to develop new approaches in 
delivering drugs to the ischemic brain.  
 
By using LXR agonist we showed a novel mode of action of LXR at the BBB, 
i.e. preservation of BBB tightness. As such, we showed that LXR activation reduces 
brain swelling and promotes BBB tightness, without influencing the polarity of ABC 
transporter expression after stroke. Our results reveal a hitherto unknown vascular 
protective mechanism, which potentially offers itself for clinical use under conditions 
of stroke-related brain edema in patients with malignant stroke. In these patients, 
brain edema leads to a rise in intracranial pressure that critically affects the patients’ 
prognosis. Until now there are still no therapies available allowing to antagonize BBB 
breakdown.  
 
By using knockout mice not expressing the lipoprotein ApoE, we furthermore 
demonstrated that ApoE controls BBB polarity presumably through ApoER2 and 
regulates the post-ischemic expression of ABCB1 and ABCC1, thereby controlling 
drug accumulation in the ischemic brain. As such, our study unraveled a novel target 
via which the access of systemically delivered drugs into the brain may be improved. 
The blood-brain access of drugs is impeded by ABC transporters, which, as we 
previously showed are regulated upon stroke in a coordinated way that makes drug 
access difficult (Spudich et al., 2006; Kilic et al., 2008). In our studies we furthermore 
showed that the regulation of BBB polarity by ApoE does not go along with changes 
in BBB tightness. Hence, different mechanisms control both features of brain 
endothelial cells.  
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Stroke occurs mainly in persons with vascular risk factors, such as 
hypercholesterolemia. For this purpose we examined the effect of a cholesterol-rich 
diet on the BBB after stroke, showing an increased permeability but unchanged 
polarity of the ischemic BBB in hypercholesterolemic animals. Our observations are 
highly relevant with respect to translational studies in ischemic stroke, which so far 
are mainly performed in animals on a regular, cholesterol-restricted diet. Such 
animals do not adequately reflect the pathophysiology of BBB changes under 
conditions of hypercholesterolemia, as we now demonstrate.  
 
 
5.2 Part I: LXR activation enhances BBB tightness but not polarity in the 
ischemic brain 
 
 There is now a large body of evidence indicating the importance of endothelial 
integrity in BBB. At the acute phase of ischemic stroke, the excessive Ca2+ influx 
into endothelial cell activates many molecular mechanisms that compromise BBB 
tightness, exacerbating neuronal injury. Therefore, there is now a growing interest in 
BBB as a therapeutic target. It is an intriguing idea that reversion of BBB function 
might be used for therapeutic purposes in CNS diseases, where neuronal injury is 
consequence of vascular disturbances, or where neuronal injury is exacerbated by 
BBB damage.   
 
For this purpose, we investigated the effect of LXR activation, which has been 
previously shown to upregulate ABC transporters on BBB tightness, by using mice 
submitted to focal cerebral ischemia.  Using protein expression and interaction 
studies, we demonstrate, for the first time, that LXR activation promotes post-
ischemic BBB tightness by mechanisms involving upregulation of LXR’s target gene 
calpastatin, deactivating calpain-1/2 and stabilizing p120 catenin. p120 catenin 
inhibits RhoA and activates Cdc42, thus restoring the post-ischemic expression and 
phosphorylation of TJ proteins and promoting their assembly. Moreover, LXR 
activation induces ABC transporters expression at the BBB without affecting BBB 
polarity. Our data provide a detailed analysis of signaling pathways involved in BBB 
integrity regulation after stroke. 
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It has previously been shown that the cysteine protease calpain-1/2 promotes 
brain injury and exacerbates edema, thus presumably increasing BBB permeability 
(Cao et al., 2007; Sedarous et al., 2003). The signal pathways via which this 
protease leads to BBB breakdown remained unknown. By showing that calpain-1/2, 
which is activated upon ischemia as a consequence of the downregulation of its 
endogenous inhibitor calpastatin (Goll et al., 2003; Sedarous et al., 2003), reduces 
p120 catenin levels in ischemic microvessels, resulting in the loss of RhoA binding to 
p120 catenin, a known GDI for RhoA (Anastasiadis et al., 2000; Noren et al., 2000), 
thus inducing RhoA overactivation, we now provide such mechanism. Indeed, the 
delivery of LXR agonist T0901317 restored calpastastin, a known LXR target based 
on transcriptional profiling studies (Hummasti et al., 2004), deactivated calpain-1/2 
and stabilized p120 catenin, reconstituting p120 catenin interaction with RhoA and 
Cdc42, which resulted in RhoA deactivation and, as p120 catenin binds GEFs 
specifically activating Cdc42, such as Vav2, in Cdc42 overactivation. That LXR 
activation deactivates calpain-1/2 is new, and modulation of Rho GTPases by LXR 
agonists to the best of our knowledge has not yet been shown. 
 
In migrating cells RhoA activation is followed by Cdc42 activation (Machacek 
et al., 2009). That both Rho GTPases respond conversely to LXR activation is 
noteworthy and may offer a clue about why the LXR agonist treatment promotes BBB 
tighntess. RhoA and Cdc42 have opposite effects on BBB tightness. RhoA activation 
destabilizes tight junction complexes via stress fibre formation, thereby inducing BBB 
leakage (Schreibelt et al., 2007; Chrissobolis and Sobey, 2006; Hirase et al, 2001), 
whereas Cdc42 activation promotes the assembly of tight junction proteins, thus 
enabling BBB tightness (Ramchandran et al., 2008; Cau et al., 2005; Fukuhara et al., 
2003). In our studies, the shift between RhoA and Cdc42 balance was accompanied 
by profound changes in the expression, phosphorylation and interaction of tight 
junction proteins occludin and ZO-1. We presume that the differential response of 
RhoA and Cdc42 to the LXR agonist is a consequence of specific interactions with 
p120 catenin, which has differential effects on activation of both small GTPases 
(Anastasiadis et al., 2000; Noren et al., 2000). Besides modulating the activation of 
Rho GTPases, T0901317 also deactivated MMP-2/9, JNK1/2 and caspase-3 in 
cerebral microvessels, which may at least partly represent downstream signals of the 
reduced calpain-1/2 activity. Previous studies already suggested a role of calpains in 
MMP-9 activation in the stroke brain (Tsubokawa et al., 2006). In microvascular 
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endothelial cells, calpain-1 was shown to translocate into mitochondria upon 
activation, inducing oxidative bursts activating MMP-2/9 (Moshal et al., 2006). 
Indeed, calpain-1 inhibitors blocked the formation of reactive oxygen species and 
prevented the MMP-9 activation (Tsubokawa et al., 2006). Regarding caspase-3, the 
proteolytic capacity of calpain-2 to facilitate the activation this executioner caspase is 
well-known. As such, calpain-2 degrades the caspase-3 full length proform into a 
29kDa fragment that may subsequently be cleaved more easily to active forms 
(Blomgren et al., 2001). This degradation has been shown to contribute to neonatal 
hypoxic-ischemic neuronal injury (Blomgren et al., 2001).  
 
More likely as a direct consequence of the activation of LXR, T0901317 
treatment increased expression levels of ABC transporters after stroke. As such, not 
only the lipid transporters ABCA1 and ABCG1, which are known targets of LXR 
based on transcriptional profiling studies (Naik et al., 2006; Hummasti et al., 2004) 
and which have been shown to be induced by T0901317 in non-cerebral vessels 
(Efanov et al., 2004; Bradley et al., 2007), but also the multidrug resistance 
transporters ABCB1 and ABCC1, which control the distribution of pharmacological 
compounds at the blood-brain interface and for which regulation by LXR has so far 
not been reported, were elevated in cerebral microvessels upon LXR activation. We 
interpret the elevation of ABC transporters as part of a coordinated response aiming 
at the maintenance of cerebral homeostasis. Interestingly, both ABC transporters, 
ABCB1 which is exclusively expressed at the luminal endothelial membrane and 
ABCC1 which is exclusively expressed at the abluminal endothelial membrane, were 
upregulated at the BBB. This observation shows that LXR activation does not affect 
BBB polarity upon stroke, therefore suggesting other mechanisms had to be involved 
in regulating BBB polarity, which still needed to be assessed. 
 
The preservation of BBB tightness by T0901317 offers new perspectives for 
the treatment of cerebrovascular diseases, where LXR agonists might be used for 
the treatment of vasogenic edema. Since LXR activation promotes BBB tightness, at 
the same time providing vascular protection, LXR agonists possess a particularly 
promising profile that might render them suitable for therapeutic purposes. 
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5.3 Part II: Apolipoprotein-E controls BBB polarity without influencing BBB 
tightness  
 
It has previously been shown that ABC transporters are regulated in a 
coordinated way on ischemic brain microvessels. As such, the luminal transporter 
ABCB1 was upregulated (Spudich et al., 2006) while the abluminal transporter 
ABCC1 was downregulated in response to stroke (Kilic et al., 2008). BBB polarity is 
an importing aspect in ABC transporters expression and function. As such, the 
luminal upregulation of ABCB1 allows drug extrusion from the ischemic brain, 
whereas the abluminal downregulation of ABCC1 decreases drug uptake by the 
ischemic brain. The mechanisms involved in BBB polarity and in the differential 
expression of ABC transporters upon stroke are largely unknown.  
 
By using protein and gene expression studies we demonstrated that ABCB1 
and ABCC1 are regulated on the transcription level after focal cerebral ischemia and 
that ApoE regulates the coordinated expression changes of both ABC transporters 
on the luminal and abluminal endothelial membrane, thereby controlling the 
accumulation of pharmacological compounds in the brain tissue. 
 
That the lipoprotein ApoE, which is involved in reverse cholesterol transport in 
the blood, regulates BBB polarity is new. ApoER2 is strongly expressed on brain 
capillaries, besides neurons (Korschineck et al., 2001). In neurons, ApoER2 has 
been shown to control synaptic plasticity, acting as receptor for the extracellular 
matrix molecule reelin (Beffert et al., 2005). ApoER2’s role on vascular cells 
remained elusive until now. 
 
Interestingly, ApoER2 was particularly strongly expressed on the abluminal 
surface of brain capillary cells in our study. This might explain why ApoE controls 
ABC transporter expression in ischemic, but not in non-ischemic brain tissue. As 
such, ApoER2 might act as a sensor for post-ischemic BBB breakdown, regulating 
ABC transporters when blood-derived proteins, namely ApoE, enter the brain 
parenchyma, thus contributing to the maintenance of tissue homeostasis. 
 
That ApoER2 forms complexes with JNK1/2 via the scaffold protein JIP1/2 in 
mouse cerebral microvessels, has already been demonstrated by bidirectional 
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immunoprecipitation studies in rat total brain extracts (Verhey et al., 2001; Stockinger 
et al., 2001). JIP1/2 in turn targets MKK-7 and MKP-7 to either phosphorylate or 
dephosphorylate JNK1/2, as previously shown in vitro (Willoughby et al., 2003). 
JNK1/2 negatively regulates ABCB1 (Liu et al., 2007) and positively regulates 
ABCC1 (Shinoda et al., 2005) transcription, as demonstrated by others in non-small 
and small cell lung adenocarcinoma cells. Transcription regulation by JNK1/2 is 
mediated by c-Jun binding to the activator protein-1 binding site of the promoter of 
both genes (Shinoda et al., 2005; Liu et al., 2007). We herein confirmed that c-Jun is 
indeed phosphorylated, i.e., overactivated upon ischemia in ApoE-/- cells, thus 
downregulating ABCB1 and upregulating ABCC1.  
 
In biodistribution studies we show that the expression changes of ABCB1 and 
ABCC1 have a profound impact on drug biodistribution, as revealed after systemic 
delivery of the neuroprotectant FK506, an ABCB1 substrate (Spudich et al., 2006). 
As such, the reduced expression of ABCB1 in ApoE-/- mice was associated with a 
five times increased access of FK506 into the ischemic brain tissue, an observation 
that was partly reversed after delivery of human ApoEε3.  
 
That ApoE controls drug biodistribution offers fascinating perspectives for 
translation studies to human stroke patients (Figure 34). Future studies will have to 
identify, if the regulation of human ABC transporters resembles that of mice. In the 
case, the receptor ApoER2 might be targeted to increase the accumulation of 
pharmacological compounds in the brain tissue. 
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Figure 34. ApoE regulates the expression of ABC transporters at the BBB: 
Upon ischemic stroke ABCB1 is upregulated at the luminal side of BBB and ABCC1 
is downregulated at the abluminal side of BBB, therefore decreasing drug uptake by 
the brain. Our findings show that upon ischemic stroke ApoE is expressed on brain 
microvessels, and controls ABCB1 and ABCC1 via its receptor ApoER2 that is 
constitutively expressed at the BBB.   
 
 
 
 
 
 
 
 
 
 
Brain drug accumulation 
high 
Brain drug accumulation 
low 
Ischemic stroke 
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5.4 Part III: Hypercholesterolemia impairs post-ischemic BBB tightness but not 
polarity 
 
The accumulation of lipids into endothelial walls forming vessels is one of the 
most important factors contributing to vascular dysfunction (Adams et al., 2000). The 
effect of hypercholesterolemia on the cardiovascular system is well studied (Paterick 
and Fletcher, 2001), where lipid accumulation into artery walls causes artery 
thickening, therefore hardening vessels wall, affecting directly blood flow and 
inducing multiple inflammatory responses, which compromise endothelial function 
(Baldassarre et al., 2002).  
 
Until now there are no reports that explicitly investigated the direct effect of 
hypercholesterolemia on BBB integrity after ischemic stroke. In our present studies 
we showed that hypercholesterolemia enhances vascular permeability without 
altering the expression of ABC transporters along the BBB, presumably via 
mechanisms involving the overactivation of calpain-1/2 and MMP-2/9. 
 
In the acute phase of stroke, calpain-1/2 are activated mainly by the 
intracellular accumulation of Ca2+ and the degradation of its endogenous inhibitor 
calpastatin (Cao et al., 2007), therefore leading to cell cytoskeleton degradation 
(Zaidi and Narahara, 1989; Stalker et al., 2003). Similarly, MMP-2/9 are activated, 
contributing in BBB disruption and leakage (Gu et al., 2002; Zhao et al., 2006). 
Calpain-1/2 and MMP-2/9 are involved in TJ degradation, compromising BBB 
integrity (Gu et al., 2002; Zhao et al., 2006; Cao et al., 2007). In agreement with 
these earlier studies, we observed in our here presented experiments that upon 
ischemia, calpain-1/2 and MMP-2/9 are activated in brain microvessels. Interestingly, 
hypercholesterolemia exacerbated the activation of both proteases, thus inducing 
occludin degradation, and contributing to BBB leakage. The increased activation of 
calpain-1/2 and MMP-2/9 upon ischemic stroke in hypercholesterolemia might be 
explained by the increased Ca2+ intracellular entry, accumulation and endothelial 
dysfunction that were observed in peripheral vascular system (Bialecki et al., 1991; 
Perrault et al., 2000).  
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Interestingly, we found an increased expression of the G protein coupled 
receptor AT1R in the ischemic brain under hypercholesterolemic conditions. Upon 
activation, AT1R has a powerful vasoconstriction function (Van Linthout et al., 2009). 
Vasoconstriction is mediated by the downstream activation of RhoA signalling 
(Bregeon et al., 2009).  Indeed, we observed in our here presented experiments that 
focal ischemia induces RhoA activation. Since hypercholesterolemia similarly 
activated a RhoA specific GEF, LARG (Ying et al., 2006; Ying et al., 2009), which is 
known to be a target of AT1R (Ying et al., 2006), we hypothesize that AT1R might 
have played a role in mediating BBB permeability induced by hypercholesterolemia. 
 
The induction of BBB permeability by hypercholesterolemia is an important 
observation with respect to translational studies, as the vast majority of animal 
experiments is presently conducted with animals receiving a cholesterol-restricted 
regular diet. Our data suggest that such animals poorly reflect the pathophysiology of 
a stroke in hypercholesterolemia. Animal models carrying vascular risk factors should 
more stringently be assessed in the stroke field in the future.   
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6 CONCLUSION AND OUTLOOKS 
 
 
In the recent past, the reasons for the failure of clinical trials in ischemic stroke 
have intensively been discussed. As such, it has been suggested that the poor 
translation of experimental stroke research and the failure of clinical trials may be 
attributed to clinically irrelevant animal models and to the focus on clinically irrelevant 
pathways. It was suggested that more emphasis should be placed on the 
cerebrovascular system, especially on the key molecular mechanisms involved in the 
evolution of injury and the mechanisms involved in the secondary injury, such as 
brain edema (Hossmann, 2009).  
 
As a consequence of such ideas, we now deciphered molecular mechanisms 
regulating two key features of the cerebrovascular system, i.e., the paracellular 
tightness of the BBB and the polarity of ABC transporters expressed on the luminal 
and abluminal membranes of the brain endothelium, showing that both features are 
independently regulated from each other, the nuclear receptor LXR regulating BBB 
tightness and the apolipoprotein ApoE changes in the luminal versus abluminal 
expression of ABC transporters upon stroke.  
 
Originally, LXR have been described as oxysterol sensors playing an 
important role in cholesterol homeostasis. LXR activation has broader effects on 
endothelial cell. Our results showed that LXR activation strategy, using synthetic 
agonists, is an interesting tool that provides endothelial protection and BBB 
restoration, thereby decreasing brain edema. This novel role of LXR activation might 
be useful in other CNS diseases, where edema is observed. 
 
ABC transporters might play a predominant role in maintaining brain 
homeostasis and protecting brain from harmful metabolites generated after cerebral 
ischemia. As such, it appears reasonable that a luminal transporter, ABCB1, which 
eliminates toxic molecules from the brain, is upregulated, whereas an abluminal 
transporter, ABCC1, which carries molecules from the blood to brain, is 
downregulated after stroke. Our results showed that ApoE controls this elegant 
defence system, thereby contributing to brain protection against toxins. Notably, ABC 
transporter expression was not influenced by hypercholesterolemia.  
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In view of the relevance of this system in preserving BBB from toxins, long 
term inhibition using molecules that bind ABCB1 and alter its function as carrier efflux 
would increase the concentration of toxins, which could be problematic for cell 
survival. From this point of view, ischemic stroke, which is an acute disease, may 
represent a particularly suitable condition for ABC transporter modulation strategies. 
ApoER2 in this context represents a promising target, which may synergistically alter 
the expression and functionality of sets of ABC transporters. We predict that by 
modulating the activity of ApoER2, the drug accumulation and efficacy may be 
improved in the ischemic brain in humans. 
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